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ABSTRACT 
Dysregulation of PI3K/Akt/mTOR pathway has been implicated in tumorigenesis and 
malignancy in numerous solid tumors.  Everolimus is a potent allosteric inhibitor of mTORC1, 
and has been approved for the treatment of number of cancers including renal and breast cancer. 
BEZ235, a dual PI3K/ mTOR inhibitor, in combination with everolimus has shown promising in 
vitro and preclinical evidence for synergistic activity against solid tumors. This led to an 
investigator initiated Phase 1b clinical trial to determine the safety, pharmacokinetics and 
pharmacodynamics of the combination of BEZ235 with everolimus in subjects with advanced 
solid tumors.  
The combination of BEZ235 and everolimus has the potential for significant 
pharmacokinetic drug-drug interaction (DDI), given the prominent role of cytochrome P450 3A4 
(CYP3A4) in the metabolism of everolimus. Thus, the integral aspect of the dissertation was to 
evaluate the pharmacokinetics of the two agents, investigate DDI and to conduct correlative 
studies to assess the mechanism(s) that may underlie this DDI. We describe here, 1) first report 
of clinical pharmacokinetics of BEZ235 at doses ranging from 200 to 800 mg/day with 
everolimus at 2.5 mg/day, and investigation of DDI, 2) correlative studies to delineate the 
mechanism of this interaction, 3) mechanistic physiologically based pharmacokinetic modeling 
(PBPK) to understand the impact of physiological and drug specific parameters on DDI. 
Phase I dose escalation consisted of 28-day study treatment cycles with BEZ235 doses 
of 200, 400 and 800 mg/day with everolimus at 2.5 mg/day. Nineteen subjects were enrolled in 
the study and blood samples were collected on days 1 and 28. We delineated the 
pharmacokinetics of BEZ23 on day 1 and day 28, which was linear and dose proportional in the 
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dose range tested. Everolimus pharmacokinetics was evaluated on day 1 and day 28, there was a 
significant increase in everolimus blood Cmax and AUC0-24 from day 1 to day 28. Everolimus 
clearance (CL/F) decreased from 24.76±2.91 L/h on day 1 to 13.41±2.31 L/hr on day 28.  
Population based and non-compartmental approaches showed that there was a 1.7 fold increase 
in everolimus when dosed with BEZ235. In correlative in vitro studies, BEZ235 was observed to 
be a time-dependent inhibitor (TDI) of CYP3A4. In primary human hepatocytes, BEZ235 had a 
potential to induce CYP3A4 based on mRNA levels however, there was no corresponding 
increase in CYP3A4 activity. A PBPK model was developed using mechanistic static and 
dynamic model to study the interaction. Prediction based on both the models were close to the 
observed interaction. PBPK simulations indicated a 5-fold reduction in gut CYP3A4 activity in 
presence of BEZ235, leading to a significant decrease in everolimus gut metabolism.  Thus, an 
increase in everolimus Fg, fraction escaping gut metabolism, when co-administered with 
BEZ235 might play a role in the observed interaction.   
Overall, Phase I study provide insights into the pharmacokinetics and suggest that the 
systemic exposure of BEZ235 and everolimus are in the levels where target inhibition was noted 
in vitro. However, the clinical outcome in the combination was not promising due to overlapping 
toxicities leading to early termination of the trial.  
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1 Introduction 
1.1 Signal Transduction Pathways and Molecularly Targeted Agents in Cancer 
Therapy 
During the past decade, molecularly targeted agents (MTA) have become a pivotal 
part of cancer therapy. Significant developments in understanding the molecular mechanisms 
underlying cancer development and progression has led to the identification of key cell signaling 
pathways (Figure 1) and characteristic “hallmarks” of oncogenesis namely; self-sufficiency in 
growth signals, insensitivity to anti-growth signals, tissue invasion and metastasis, evasion of 
apoptosis, limitless replicative potential, sustained angiogenesis, deregulated metabolism, 
evading immune system, genomic instability and inflammation  (Hanahan & Weinberg, 2000, 
2011). New generation of MTAs are rationally designed to selectively inactivate key genetic 
markers leading to oncogenesis in specific tumors. Discovery of imatinib, a small molecule 
tyrosine kinase inhibitor targeting aberrant Bcr-Abl kinase, resulted in a dramatic response in 
chronic myelogenous leukemia (CML) patients (Michor et al., 2005). Several small molecules 
and monoclonal antibodies are rationally designed to inhibit specific proteins or pathways 
deregulated in cancers. MTA’s are characterized by inherent tumor specificity, greater clinical 
efficacy, and lower normal tissue toxicity (Kummar et al., 2010; Sawyers, 2004). Although there 
have been few MTAs successful as monotherapy, especially targeting the epidermal growth 
factor receptor (EGFR) (Lynch et al., 2004; Shepherd et al., 2005) and vascular endothelial 
growth factors (VEGFRs) (J. C. Yang et al., 2003), MTA’s targeting multiple pathways or 
combination of MTA’s are recommended for effective cancer therapy (Kwak, Clark, & Chabner, 
2007; Park, Davis, Doroshow, & Kummar, 2013). The phosphatidylinositol 3-kinase, Akt and 
16 
 
mammalian target of rapamycin pathway (PI3K/Akt/mTOR) kinase is a key intracellular 
signaling pathway and deregulation of this signaling pathway has been implicated in 
tumorigenesis and malignancy in a number of cancers such as breast, colon, endometrial, renal 
and hepatocellular carcinoma (Rodon, Dienstmann, Serra, & Tabernero, 2013). 
 
Figure 1: Overview of cell signaling pathways – highlighting PI3K/Akt/mTOR pathway 
activated by integrins, receptor tyrosine kinases, cytokine receptors, G-protein-coupled 
receptors and other stimuli  and its role in regulating diverse cellular functions including 
metabolism, growth, proliferation, survival, transcription and protein synthesis.   
(Illustration reproduced courtesy of Cell Signaling Technology, Inc. www.cellsignal.com) 
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1.1.1 PI3K/Akt/mTOR - Key Cell Signaling Pathway 
PI3K/Akt/mTOR pathways plays a crucial role in most cellular processes involved in 
“hallmarks of cancer”, including cell proliferation, survival, metabolism, genomic instability, 
and also contributes to cancer promoting aspects of the tumor environment, such as angiogenesis 
and inflammatory cell recruitment (Figure 2) (Engelman, 2009; Hanahan & Weinberg, 2011; 
Osaki, Oshimura, & Ito, 2004). Further, genetic analysis of a number of cancers suggests that 
PI3K/Akt/mTOR pathway is most frequently deregulated with several somatic mutations 
identified in the genes encoding for the pathway (Samuels et al., 2004). This strong genetic 
evidence along with the central, fundamental role of PI3K/Akt/mTOR pathway to all cancer cells 
provided a unique opportunity to combat cancer by targeting this pathway through MTAs  
(Figure 2). 
The PI3Ks are intracellular heterodimeric lipid kinases that convey extracellular cell 
signals, initiating and catalyzing a plethora of intracellular signaling pathways (Rameh & 
Cantley, 1999). PI3Ks are divided into three classes (Class IA, IB, II and III) based on their 
structural characteristics and substrate specificity (Domin & Waterfield, 1997). Class IA is the 
most extensively studied and it has three p110 catalytic subunits (p110α, p110β and p110δ) and a 
regulatory subunit, p85 (Jia, Roberts, & Zhao, 2009; Thorpe, Yuzugullu, & Zhao, 2015). Class I 
PI3Ks catalyzes the phosphorylation of phosphatidylinositol (4,5)-bisphosphate (PIP2) to 
phosphatidylinositol (3,4,5)-trisphosphate (PIP3), in response to extracellular stimuli such as 
activated receptor tyrosine kinases, or G-protein coupled receptors (Stoyanov et al., 1995; 
Walker, Perisic, Ried, Stephens, & Williams, 1999). Lipid messenger PIP3 recruits and activates 
phosphatidylinositol-dependent kinase 1 (PDK1), which in turn phosphorylates and activates 
protein kinase B (PKB, also known as Akt). The tumor-suppressor phosphatase with tensin 
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homology (PTEN) negatively regulates PI3K signaling by dephosphorylating PIP3, converting it 
back to PIP2. One of the major differences between the isoforms is that, RTKs activate p110α 
and p110δ isoforms whereas, p110β and p110γ are activated through G-protein–coupled receptor 
(GPCRs) (Engelman, 2009; Porta, Paglino, & Mosca, 2014; Walker et al., 1999). Another 
interesting aspect is the differential tissue distribution of PI3K isoforms, p110α and p110β 
isoforms are ubiquitously expressed, while p110δ and p110γ are found predominately in 
leukocytes (Jia et al., 2009). There is increased interest in understanding the role of this selective 
distribution of PI3K isoforms. Other than Akt, PI3K also activates serum/glucocorticoid 
regulated kinase 3 (SGK3) and Bruton’s Kinase (BTK) downstream (Hall, Kim, Skor, & 
Conzen, 2012; Qiu & Kung, 2000). PI3K/Akt activation regulates a number of pathways 
involved in cell growth, proliferation, motility, neovascularization, adhesion, and apoptosis 
(Faber et al., 2009; Gericke, Munson, & Ross, 2006; Zhao et al., 2006).   
Mammalian target of rapamycin (mTOR), is one the critical downstream effectors of 
Akt. mTOR kinase is conserved in most eukaryotes which plays a crucial role in the regulation 
of cell growth and proliferation by controlling cellular energy, oxygen levels, nutrient 
availability, and mitogenic signals (Dancey, 2010; Guertin & Sabatini, 2007; Hudes, 2009; 
Sarbassov, Guertin, Ali, & Sabatini, 2005). It activates downstream signaling effectors that play 
a key role in regulating cell survival and proliferation. mTOR exists as two complexes mTORC1 
and mTORC2 (Dancey, 2010; Guertin & Sabatini, 2007; Sarbassov et al., 2005). The mTORC1 
complex is composed of the mTOR catalytic subunit, regulatory associated protein of mTOR 
(RAPTOR), proline rich Akt substrate 40 kDa (PRAS40) and  protein mLST8. The mTORC2 is 
composed of mTOR, RICTOR (rapamycin-insensitive mTOR), mammalian stress-activated 
protein kinase interacting protein 1 (MSIN1) and mLST8 (H. Yang et al., 2013). mTORC1 plays 
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a central role in cellular metabolism and biosynthesis, and is regulated by complex inputs from 
growth factors and nutrients (Sarbassov et al., 2004). The most studied effectors downstream of 
mTORC1 are the ribosomal protein S6 kinases (S6K) and the protein synthesis initiation factor 
4E-binding proteins (4E-BP1) (Sarbassov et al., 2004; Sarbassov et al., 2005). mTORC2 
mediates activation of PKB/AKT and SGK1 (Sarbassov et al., 2004). The mTOR complexes are 
key regulators of multiple cellular processes including translation, growth, proliferation, 
metabolism, and autophagy (Sarbassov et al., 2004; Sarbassov et al., 2005). Further, mammalian 
target of rapamycin (mTOR) has also been found to be abnormally activated in a number of 
tumor types (Faber et al., 2009; Luo, Manning, & Cantley, 2003). Together, the 
PI3K/AKT/mTOR pathway regulates the transition of several important proliferative and 
angiogenic factors, such as c-myc, cyclin D1, HIF1 α, and VEGF.  Excessive signaling through 
the PI3K/AKT/mTOR cascade has been shown to be both prognostic as well as predictive 
marker in many solid tumor types (Liao et al., 2012; Ogino et al., 2013; Ogino et al., 2014). 
Consequently, targeting the PI3K/AKT/mTOR pathway has been increasingly recognized as a 
therapeutic strategy in the treatment of many cancer types such a renal cell carcinoma (RCC), 
glioblastoma multiforme (GBM), hepatocellular carcinoma (HCC) and breast cancer (Baselga, 
Campone, et al., 2012; Courtney, Corcoran, & Engelman, 2010; Figlin, Kaufmann, & Brechbiel, 
2013). 
1.1.2 Activation of PI3K/Akt/mTOR in Cancer 
Upregulation of PI3K/Akt/mTOR pathway is prevalent in many tumor types. The two 
major mechanisms for activation of PI3Ks are either through external RTKs or through somatic 
mutations in the gene encoding for the pathway.  Activation through mutations or amplification 
in RTKs such as epidermal growth factor receptor (EGFR, HER2), c-KIT and c-MET have been 
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described in multiple tumor types, which further activate PI3K downstream which drives the 
tumor growth and proliferation (Jia et al., 2009).  
Moreover, dysregulation of PI3K signaling may be caused by mutations in PI3K itself, 
or in PTEN phosphatase, or by a variety of factors both upstream and downstream of PI3K. 
PTEN mutations are reported in prostate and endometrial carcinoma, melanoma, and 
glioblastoma and may involve somatic mutation, deletion, or methylation of PTEN (Cho, 2014). 
Amplification of p110α is frequently associated with various types of cancers, including head 
and neck, lung, thyroid and cervical cancer. In addition, somatic mutations in PIK3CA gene, the 
gene encoding the p110α catalytic subunit of PI3K, have been associated with a number of 
cancers including 30% of colorectal, glioblastomas, breast, prostate and endometrial cancers. 
Recently, two hotspot regions on exons 9 (E542K and E545K) and 20 (H1047R) in PI3KCA 
gene were identified which are associated with constitutive activity of the pathway (Janku et al., 
2011). 
1.1.3 Targeting PI3K/mTOR Pathway 
1.1.3.1 mTOR Inhibitors 
Rapalogs, the first generation mTOR inhibitors, consist of rapamycin (sirolimus) and 
its derivatives RAD001 (everolimus), CCI‐779 (temsirolimus), and AP‐23573 (deforolimus/ 
ridaforolimus) (Table 1) (Meric-Bernstam & Gonzalez-Angulo, 2009). Rapalogs form a complex 
with the intracellular immunophilin FK506-binding protein 12 (FKBP12), and the FKBP12–
rapamycin complex then binds to the FRB domain in mTOR complex inhibiting it allosterically 
(Bjornsti & Houghton, 2004; Dutcher, 2004; Vignot, Faivre, Aguirre, & Raymond, 2005). 
Rapamycin, a macrocyclic lactone, was first isolated from Streptomyces Hygroscopicus, which 
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was initially developed as an antifungal agent with immunosuppressive properties (Sabatini, 
2006). Rapamycin gained approval for the prevention of acute rejection in combination with 
cyclosporine and steroids by US-FDA in 1999. The potential of rapalogs as an anticancer agent 
was identified in early 1980s, and it was found to inhibit the growth of several human and 
murine cancer cell lines in a concentration-dependent manner (Benjamin, Colombi, Moroni, & 
Hall, 2011). In preclinical and clinical studies, rapalogs showed a potent cytostatic activity as a 
single agent and had synergistic effect when given in combination with cytotoxic anti-cancer 
agents such as cisplatin, doxorubicin, 5-fluorouracil, gemcitabine, paclitaxel and with radiation 
(Bjornsti & Houghton, 2004; Motzer et al., 2008). Concerning physiochemical and 
biopharmaceutical properties, it should be noted that rapamycin is insoluble in aqueous solutions 
and has very low oral bioavailability, which led to developing rapamycin analogs with 
significantly improved pharmacokinetic properties (Table 1). For instance, temsirolimus 
(CCI779), is an ester derivative prodrug of rapamycin, which was approved for the treatment of 
renal cell carcinoma in 2007 (Pinto Marin et al., 2012). Everolimus (RAD001) is a hydroxyethyl 
ether derivative of rapamycin with better aqueous solubility and available as an oral formulation. 
Ridaforolimus (AP23573) has a substitution of a phosphate group at C‑42 of rapamycin to 
improve aqueous solubility and oral bioavailability. Though rapalogs have been approved for 
cancer therapy, one of the major impediment in obtaining optimal clinical responses with mTOR 
inhibitors alone is the incidence of a negative feedback leading to activation of PI3K and its 
downstream effectors (Akt and mTOR) (Gomez-Pinillos & Ferrari, 2012; Sarbassov et al., 2006; 
Zitzmann et al., 2010). Furthermore, recent studies show that effect of rapalogs on 4E-BP1 is 
transient compared to the inhibition of S6 kinase (O'Reilly et al., 2006; Wander, Hennessy, & 
Slingerland, 2011). To overcome these potential drawbacks, ATP binding site mTOR inhibitors 
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were developed which inhibit both the mTORC1 and mTORC2 complexes (Rodon et al., 2013). 
Preclinical studies show that their mTORC1 inhibition is much stronger than rapamycin 
derivatives and might likely account for their increased anti-proliferative activity compared with 
rapamycin. Some of mTOR catalytic site inhibitors in development are AZD-8055, OSI-027 and 
CC-223 (Rodon et al., 2013; Wander et al., 2011). 
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Table 1: Structure and properties of rapalogs. Rapamycin and its derivatives (rapalogs) by 
modification at the C-43 position.  
 
Rapamycin 
C51 H79 N O13 
Molecular Weight:   914.17  
Other Names 
Rapamune, SIIA 9268A, Sirolimus, 
Supralimus, Wy090217 
Formulation: Oral  
Recommended dose: 2- 5 mg/day 
 
Ridaforolimus 
C53 H84 N O14 P 
Molecular Weight :   990.21 
Rapamycin, 42-(dimethylphosphinate) 
Other Names 
AP 23573,  Deforolimus, MK 8669 
Formulation: Oral and intravenous 
Recommended dose: 12.5 mg per day for 5 
days followed by 75 mg weekly for 2 weeks
 
Temsirolimus 
C56 H87 N O16 
Molecular Weight : 1030.29 
42-[3-hydroxy-2-(hydroxymethyl)-2-
methylpropanoate]-Rapamycin 
Other Names 
CCI 779, Temsorolimus, Torisel 
Formulation: Oral  
Recommended dose: 2- 5 mg/day 
 
Everolimus  
C53 H83 N O14 
42-O-(2-hydroxyethyl)- Rapamycin 
Molecular Weight:   958.22 
Other Names 
RAD, RAD001, SDZ-RAD, Afinitor, 
Certican 
Formulation: Oral  
Recommended dose: 10 mg per day / 20–70 
mg weekly 
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1.1.3.2 Class I PI3K Inhibitors  
PI3K inhibitors are divided into three classes, pan-class I, isoform-selective and dual 
PI3K/mTOR inhibitors, based on isoform selectivity for the ATP binding site of PI3Ks. The pan-
PI3K inhibitors inhibit all class IA p110 isoforms (Edgar et al., 2010; Safina et al., 2012). The 
first generation PI3K inhibitors such as wortmannin and  LY294002 target the catalytic site of all 
class I PI3K by different mechanisms (S. P. Davies, Reddy, Caivano, & Cohen, 2000; Garcia-
Echeverria & Sellers, 2008; Walker et al., 2000; Wymann et al., 1996). Wortmannin is an 
irreversible inhibitor of PI3K, whereas LY294002 is a reversible ATP-competitive inhibitor (S. 
P. Davies et al., 2000). Both these compounds exhibited a significant amount of off-target effect 
leading to considerable toxicity in preclinical animal studies, curbing further development. 
However, they provided the framework for understanding the biological importance of PI3K 
signaling pathway in cancer and provided a platform for the discovery of novel isoform specific 
PI3K inhibitors. Currently, a number of pan-PI3K-targeted compounds are being introduced into 
clinical trials (Table 2).  
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Table 2: Novel new chemical entity (NCE) in the clinical development targeting various nodes of 
PI3K/Akt/mTOR pathway 
Inhibitor 
Class NCE name 
Pharmaceut
ical 
Company 
Clinical deve
lopment  
Phase 
Reference 
Pan-class I 
PI3K 
GDC-0941 Genentech 1, 2 (Sarker et al., 2015) 
NVP-
BKM120 Novartis 1, 2 
(Bedard et al., 2015; Hyman et 
al., 2015) 
XL147 
(SAR245408) Sanofi 1, 2 
(Brown et al., 2015; Matulonis 
et al., 2015; Soria et al., 2015) 
PX-866 Oncothyreon 1, 2 (Bowles et al., 2013; Pitz et al., 2015) 
BAY80-6946 Bayer 1, 2 (Morschhauser et al., 2013) 
Isoform-selective PI3K 
p110α 
NVP-
BYL719 Novartis 1, 2 (Fritsch et al., 2014) 
MLN1117 Millennium 1 (Juric et al., 2015) 
p110β 
AZD8186 Astra-Zeneca 1 (Hancox et al., 2013) 
SAR260301 Sanofi 1 (Virone-Oddos et al., 2013) 
GSK2636771 GSK 1 (Blackman et al., 2012) 
Idelalisib 
(GS-1101) Gilead approved 
(Fruman & Cantley, 2014; Q. 
Yang, Modi, Newcomb, 
Queva, & Gandhi, 2015) 
p110δ 
AMG 319 Amgen 1 (Glenn et al., 2013) 
GS-9820 Gilead 12 (Tonino et al., 2013) 
mTOR 
kinase 
inhibitor 
MLN0128 Millennium 1 (Infante et al., 2013) 
AZD2014 Astra-Zeneca 1, 2 (Basu et al., 2015) 
OSI-027 OSI/Estellas 1 (Tan et al., 2010) 
CC-223 Celgene 1, 2 (Johanna C Bendell et al., 2015) 
Dual 
PI3K/mTOR 
inhibitor 
 
 
NVP-
BGT226 Novartis 12 (B Markman et al., 2012) 
XL765 
(SAR245409) Sanofi 1, 2 (Papadopoulos et al., 2014) 
GDC-0980 Genentech 1, 2 (Powles et al., 2014) 
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1.1.3.3 Dual PI3K/mTOR Inhibitors 
Most of the dual PI3K–mTOR inhibitors target the p110α, β and δ isoforms, along 
with inhibiting mTOR complex C1 and C2. The crystal structure of p110 subunits of PI3K share 
similarities with mTOR, and small molecule inhibitors of p110 often inhibit mTOR (Maira et al., 
2008). The dual PI3K–mTOR inhibitors are advantageous in that it effectively overcomes PI3K–
Akt signaling in cancers with PIK3CA mutations, PIK3R1 mutations, PTEN loss and RTK-
dependent activation (Fan et al., 2007).  They also have potential to be effective in cancers with 
Akt mutations or amplifications, as both PI3K and mTORC2 activity might be required for full 
Akt activation. In addition, they might overcome the negative feedback activation of PI3K after 
mTORC1 inhibition, which leads to resistance in therapy to rapalogs (Fan et al., 2007). Further, a 
single agent with dual specificity greatly reduces the development of resistance, as the tumor is 
unlikely to generate two resistant kinases during the course of treatment (Liu, Cheng, Roberts, & 
Zhao, 2009).  Agents such as BEZ235, BGT226, GDC-0980 and XL765 have been developed as 
dual inhibitors of PI3K and mTOR (Table 2) (Dienstmann, Rodon, Serra, & Tabernero, 2014; B 
Markman et al., 2012; Papadopoulos et al., 2014; Powles et al., 2014).  
1.1.3.4 Isoform Specific PI3K Inhibitors 
More recently, isoform-specific PI3K inhibitors have been developed to overcome the 
off-target effects and offer the potential of complete inhibition of the relevant target (Table 2). 
PI3Kα specific inhibitors such as NVP-BYL719, GDC0032, and MLN1117 have shown early 
clinical activity in HER2- or KRAS driven breast tumors (Edgar et al., 2010; Fritsch et al., 2014; 
Juric et al., 2015). GSK2636771, AZD8186, SAR260300 are some of the PI3Kβ specific 
inhibitors in development (Blackman et al., 2012; Hancox et al., 2013; B. Li, Sun, Jiang, 
Thrasher, & Terranova, 2014; Virone-Oddos et al., 2013). Most striking efficacy was observed 
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with PI3Kδ specific inhibitor, GS1101 (idelalisib), which has been approved treatment of 
patients with relapsed chronic lymphocytic leukemia (CLL), in relapsed follicular B-cell non-
Hodgkin lymphoma and in relapsed small lymphocytic lymphoma (SLL). The overall response 
rate of GS1101 arm was 81%, compared to 13% in the control group. The median progression-
free survival was 5.5 months with the control combination but was not reached (at least 10.7 
months) with GS1101 arm (Fruman & Cantley, 2014; Gopal et al., 2014; Kahl et al., 2014). 
1.1.3.5 Challenges in Targeting PI3K/Akt/mTOR Pathway 
One of the primary challenges associated with PI3K/Akt/mTOR inhibitors is 
identifying a dose range that effectively inhibits all p110 isoforms, mTORC1 and mTORC2 
while being safe and well tolerated in patients (Fruman & Rommel, 2014; McNamara & 
Degterev, 2011).  Traditional Phase I clinical trial exploring maximum tolerated doses of these 
inhibitors further impedes the success of these agents owing to ‘all or nothing’ threshold for 
tumor responses. Moreover, PI3K/mTOR inhibitors commonly seem to have off-target effects on 
other members of the PI3K‑related kinase (PIKK) which might lead to cellular toxicity. For 
instance, BKM120 has off-target effects on tubulin and causes general cellular toxicity at 
concentrations needed to fully inhibit PI3K pathway (Brachmann et al., 2012; Saura et al., 2014). 
Recent findings also illustrate the critical role of PI3K (p110α) pathway in normal physiological 
growth and protection of heart, and inhibitors of PI3K (p110α) may cause a higher incidence of 
heart failure in patients (McMullen & Jay, 2007).  
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1.2 Combination Therapies of Molecularly Targeted Agents  
1.2.1 Opportunities and Challenges  
It is evident that cancers are dependent on a number of altered molecular pathways and 
have diverse mechanisms of intrinsic resistance to therapy with single agents. Development of 
MTAs, small molecule or antibodies directed against a specific oncogenic target, have 
transformed cancer therapy leading to improved survival and extended disease control (Baselga, 
2006). However, only few MTAs, such as imatinib for chronic myelogenous leukemia and 
trastuzumab for HER2-expresing breast cancers, have been successful as single agents. Some of 
the anecdotal responses to single agents are short-lived due to changes in a downstream effector 
leading to resistance or evolving mutations in the primary target leading to cancer progression 
(Doroshow & Kummar, 2014; Park et al., 2013). For instance, clinical response of vemurafenib, 
a highly selective BRAF inhibitor, in majority of patient is temporary and incomplete, despite its 
marked initial response rate of 81% (Flaherty et al., 2010). Interestingly, DiMasi et.al reported 
that only 13.4% of the MTAs that entered clinical testing between 1993 and 2002 were approved 
by FDA (DiMasi, Reichert, Feldman, & Malins, 2013).  
The genetic complexity of most human cancers by harboring aberrations in more than 
one molecular target or pathway, necessitates the need for inhibiting multiple signaling pathways 
and a number of combinations of MTAs are under study (Doroshow & Kummar, 2014). A 
number of strategies in selection of combination drugs include a) horizontal blockade - drugs 
targeting key parallel pathways (e.g., Akt and MEK inhibitor) b) vertical blockade - drugs 
targeting multiple targets of the same pathway (e.g., BRAF and MEK inhibitor) (Al-Lazikani, 
Banerji, & Workman, 2012; Yap, Omlin, & de Bono, 2013). Whereas combination strategies 
have generally focused on developing novel agents in combination with already approved 
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antitumor drugs, the recent release of draft guidance by the US Food and Drug Administration 
(FDA) on the development of novel-novel investigational drug combinations has encouraged the 
co-development of two novel investigational agents in combination simultaneously (Food and 
Drug Administration -Guidance for Industry, 2013). A good example is the addition of 
pertuzumab to the combination of trastuzumab and docetaxel which resulted in an increase in 
grade 3 diarrhea and febrile neutropenia, but there was a significant improvement in progression-
free survival (PFS) compared with trastuzumab and docetaxel (18.5 months versus 12.4 months; 
hazard ratio 0.62) in patients with HER2-positive metastatic breast cancer (Baselga, Cortes, et 
al., 2012; Swain et al., 2013).  
1.2.2 Role of Pharmacokinetic Evaluation in a Phase I Trial of Combination Drugs 
The Phase I trial evaluating drug combination is the critical step and presents specific 
challenges, such as the optimum selection of agents to combine among the range of possible 
combinations; the selection of the appropriate dose and schedule (including which drug or drugs 
to dose escalate); drug–drug interactions; and overlapping toxicities. Recently, the “Clinical Trial 
Design Task Force of the NCI Investigational Drug Steering Committee” recommendations on 
the design of Phase I combination trials highlight the importance of pharmacokinetic assessments 
of drug–drug interaction for the combination (Paller et al., 2014). Pharmacokinetic interactions 
in the combination may be the underlying reason for some of the reported failures, or even more 
likely, adverse pharmacodynamic interactions. Pharmacokinetic parameters such as AUC to the 
dose, inter-individual and intra-individual pharmacokinetic variability, and the impact of 
interaction in the combination are critical. Recently, there were a number of reports highlighting 
the importance of these fundamental pharmacokinetic issues in the successful development of 
oncology compounds (Bins, Ratain, & Mathijssen, 2014; Paller et al., 2014). 
30 
 
1.2.3 Recommended Dose for Phase II  
The primary goal of Phase I studies in oncology is to define a recommended Phase II 
dose (RP2D) for the combination of drugs in the target cancer patients (Goodwin, Giaccone, 
Calvert, Lobbezoo, & Eisenhauer, 2012). Typically, in Phase I studies involving cytotoxic 
chemotherapy agents, the maximum tolerated dose (MTD) was always recommended as the 
RP2D dose (Parulekar & Eisenhauer, 2004). However, in Phase I studies involving MTAs, a 
pharmacologically active dose based on preliminary biomarker evidence of target inhibition is 
explored and some studies often identify specific target patient populations which might 
responded better to the therapy (Sleijfer & Wiemer, 2008; Tanaka et al., 2008). The FDA 
initiative to grant “Breakthrough Designation” based on data from Phase I trials as a basis for 
accelerated drug approval has led to the increased use of preliminary biomarker for efficacy 
measures (Sherman, Li, Shapley, Robb, & Woodcock, 2013). There have been 23 drugs 
approved with the Breakthrough Therapy designation as of April 2015 and 13 of them were first 
time approvals for novel drugs (Ning et al., 2014; Sherman et al., 2013; Woodcock, 2014). 
Rather than MTD, the emphasis of most of these trials was on finding an optimal dose of 
targeted agent to achieve maximum inhibition of a specific target enzyme or pathway leading to 
pharmacological response.  
Over the past decade, there has been a paradigm shift in the design of clinical trials for 
MTAs, where Phase II studies are performed frequently with one dose level (Doroshow & 
Kummar, 2014; Seymour et al., 2010; Sherman et al., 2013). In case of other therapeutic agents 
and with cytotoxic agents, it was common to have multiple dose-finding studies in Phase II (Le 
Tourneau, Lee, & Siu, 2009). Although this might initially look like a tremendous improvement 
in efficiency and reduction in cost, this often results in improper dose selection which leads to 
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early termination of trials (Ferte, Soria, & Penel, 2011). Higher doses might not increase the 
response and may only increase the off-target toxicities, especially in the case of combination 
trials involving MTAs. While the choice of a given combination is based on preclinical 
pharmacological interactions/synergism at the target pathway, very little information is available 
on the putative enhancement in toxicity in normal cell biology. In spite of numerous 
combinations of MTAs entering clinical trials, there are very few positive outcomes and the 
majority of the combinations have been intolerable in patients. For instance, when sorafenib, a 
small molecule inhibitor of BRAF, CRAF, c-KIT, and VEGFR kinases, was combined with 
temsirolimus, an mTORC1 inhibitor, in a Phase I study, doses of sorafenib up to 400 mg with 
temsirolimus at 25 mg weekly was established as the MTD. However, in a follow-up Phase II 
study, the use of this dose combination resulted in increased grade 3–4 adverse events compared 
to the single agents; grade 3 thrombocytopenia incidence increased from 1% to 47% and 
hypophosphatemia from 4% to 21% (M. A. Davies et al., 2012). Similarly, a higher incidence of 
grade 3–4 toxicities were reported with half the MTD dose (5 mg/day) of everolimus, an 
mTORC1 inhibitor, combined with erlotinib (150 mg/day), an EGFR inhibitor (Besse et al., 
2014; Johnson, Jackman, & Janne, 2007; Papadimitrakopoulou et al., 2012). Out of a number of 
reasons for the increased toxicities, pharmacokinetic interaction resulting in an increased 
systemic and/or tissue concentrations cannot be overlooked. Only 22% of the Phase I studies 
evaluate a correlative analysis of pharmacokinetic findings to observed toxicity or efficacy 
(Comets & Zohar, 2009). Recently, Kenny et.al, reported that most of the tyrosine kinase 
inhibitors have a potential to inhibit CYP enzymes and have shown that both sorafenib and 
erlotinib are mild-moderate inhibitors of CYP3A, primary enzyme in the metabolism of 
everolimus and temsirolimus (Kenny et al., 2012). However, no detailed pharmacokinetic 
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interaction studies were performed at the Phase I or II studies. A high inter-patient variability in 
pharmacokinetics was reported as a reason for the lack of a pharmacokinetic interaction study in 
in sorafenib (Kelley et al., 2013). However, in case of study of everolimus with erlotinib there 
were no reasons reported for the lack of interaction study (Papadimitrakopoulou et al., 2012). 
Author’s indicate that a further refinement in the dose and/or dosing schedule will be needed in 
future clinical trials to investigate a pharmacokinetic interaction. The limited number of subjects 
in Phase I studies and the multifaceted nature of the drug interaction pose significant challenges 
in the identification and quantitative assessment of complex drug interactions. Recently, in vitro 
models of metabolism and transport along with mechanistic modeling and simulation along with 
simultaneous incorporation of multiple pathophysiological factors, have allowed for in vitro–in 
vivo extrapolation, and emerging as a valuable tool for quantitative assessment and prediction of 
complex drug interactions (Rostami-Hodjegan, 2012; Sharma, Maitland, & Ratain, 2012). 
Further, Wu et.al studying the reporting of pharmacokinetic interactions in Phase I studies 
involving a combination of two oncology products, indicated the importance of preclinical 
mechanistic rationale during the trial design. Out of 152 Phase I studies only 2% of the studies 
observed a clinically relevant drug-drug interaction (DDI) without a rationale based on 
preclinical mechanistic model, compared to 32% of the studies with a rationale. It is imperative 
to design the combination Phase I trial to investigate the pharmacokinetic interactions preferably 
based on preclinical mechanistic studies  (K. Wu, House, Ramirez, Seminerio, & Ratain, 2013).  
1.3 Everolimus – mTOR Inhibitor 
Everolimus (RAD001) is a semi-synthetic derivative of rapamycin where the hydroxyl 
at position 40 has been alkylated with a 2-hydroxyethyl group.(40-0-(2-hydroxyethyl)–
rapamycin developed by Novartis (Table 1). This modification led to improved physicochemical 
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and pharmacokinetic properties with respect to rapamycin, increasing the bioavailability of 
everolimus by 60% higher compared to rapamycin (Crowe, Bruelisauer, Duerr, Guntz, & 
Lemaire, 1999).  
1.3.1 Clinical Development of Everolimus 
Everolimus is a potent inhibitor of mTORC1 with IC50 of 1.8-2.6 nmol/L, affecting 
downstream activity of S6 ribosomal protein kinase (S6Kl) and eukaryotic elongation factor 4E-
binding protein (4E-BP1) (Sabatini, 2006) (Figure 2). Everolimus inhibited the proliferation of a 
wide variety of human solid tumor cell lines both in vitro and xenograft models. In a pancreatic 
tumor model in rat (female Lewis rats bearing subcutaneous CA20948 pancreatic tumor), 
everolimus was evaluated at doses 0.5 or 2.5 mg/kg daily, or 5 mg/kg twice weekly, or 0.5, 1, 2, 
3, or 5 mg/kg weekly. There was a significant antitumor activity in both daily and intermittent 
treatment schedules, and mTOR activity correlated well to 4E-BP1 and S6K1 levels in tumor, 
skin, and peripheral blood mononuclear cell (PBMC) (Boulay et al., 2004; Tanaka et al., 2008). 
Based on these data, a Phase I dose-escalation study was conducted in advanced cancer patients 
using both daily and weekly schedules of everolimus ranging from 5 mg/day to 30 mg/week and 
molecular markers of 4E-BP1 pathway (total and phosphorylated) and the S6K1 pathway (total 
and phosphorylated) in the tumor and skin was used as a biomarker for pharmacokinetic-
pharmacodynamic (PK/PD) modeling (Tanaka et al., 2008). An everolimus concentration of 10-
35 ng/mL was observed to be essential for sustained inhibition of mTOR pathway and 
recommended doses were 10 mg/day, or 50 mg/week. Some of the observed toxicities included 
stomatitis, neutropenia, hyperglycemia, and fatigue (O'Donnell et al., 2008). Everolimus has 
been approved for the treatment of a) advanced renal cell carcinoma (RCC) in adults after failure 
of treatment with sunitinib or sorafenib; (Motzer et al., 2008) b) progressive neuroendocrine 
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tumors of pancreatic origin (PNET) that is unresectable, locally advanced or metastatic; (Pavel et 
al., 2011) c) adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not 
requiring immediate surgery; (Franz et al., 2013) d) adults and children ≥ 3 years of age with 
subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TSC); (Franz 
et al., 2013; Krueger et al., 2010) e) postmenopausal women with advanced hormone receptor-
positive, HER2-negative breast cancer in combination with exemestane after failure of treatment 
with letrozole or anastrozole (Baselga, Campone, et al., 2012; Franz & Weiss, 2012; Yao et al., 
2011; Yardley et al., 2013). Further, there are number of clinical studies investigating the 
combination of everolimus with targeted therapies and chemotherapeutic agents.  
1.3.2 Clinical Pharmacology of Everolimus 
Clinical pharmacokinetics of everolimus has been extensively characterized in patients 
with advanced solid tumors, healthy subjects, organ transplant recipients, and have been shown 
to be not affected by age, gender, or weight of subjects (Kovarik, Hsu, McMahon, Berthier, & 
Rordorf, 2001; Kovarik et al., 2003; O'Donnell et al., 2008; US-FDA - clinical pharmacology 
and biopharmaceutics review). In patients with advanced solid tumors, time to peak everolimus 
concentrations (Tmax) occurs 1.3–1.8 hours following oral administration and the half-life was 
approximately 39 hours after a single 10 mg oral dose. The area under curve (AUC) after single 
dose everolimus was dose-proportional over the 5 – 70 mg dose range, however, the 
concentration maximum (Cmax) was dose-proportional between 5 and 10 mg, and at doses above 
20 mg the increase in Cmax was less than dose-proportional (Budde et al., 2004; US-FDA - 
clinical pharmacology and biopharmaceutics review). Everolimus Cmax and AUC0-24 (mean ± 
SD) in patients with advanced solid tumors were 32.4 ± 15.3 ng/mL and 173 ± 26 ng·h/mL, 
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respectively, with everolimus 5 mg/day and was 69.1 ± 8.1 ng/mL and 296 ± 91.7 ng·h/mL 
respectively, with everolimus 10 mg/day (O'Donnell et al., 2008).  
The everolimus uptake to human erythrocytes was approximately 85% at the blood 
concentration range of 5 - 100 ng/mL, when the percentage in plasma was around 14% 
(Laplanche, Meno-Tetang, & Kawai, 2007). The free fraction in human plasma was 0.25 and 
considered concentration independent. Everolimus is extensively metabolized to from six 
metabolites mainly via oxidative metabolism by Cytochrome P450 (CYP) enzymes (Figure 3), 
ring-opened hydrolysis product of everolimus (PKF229-255), seco acid of everolimus (PKF226-
320), 46-hydroxy metabolite of everolimus (46-0H-RAD), 24- and 25-hydroxylated metabolites 
of everolimus (24-0H-RAD & 24-0H-everolimus) and a direct phosphatidylcholine conjugate of 
everolimus.  It is primarily metabolized by CYP3A4/5 and also by CYP2C8 and the relative 
contributions are 93% and 7%, respectively (Picard, Rouguieg-Malki, Kamar, Rostaing, & 
Marquet, 2011). 
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Figure 2: Schematic representation of PI3K/Akt/mTOR signaling and combination of novel 
inhibitors BEZ235 and everolimus. BEZ235 is an ATP binding competitive dual 
PI3K/mTOR inhibitors which inhibits PI3K and both mTOR complexes C1 and C2. 
Everolimus is an allosteric inhibitor of mTORC1. 
Everolimus has been shown to be a substrate for P-glycoprotein (P-gp encoded by 
mdr1) in cell culture models and in mdr1-deficient mice (Lamoureux, Picard, Boussera, Sauvage, 
& Marquet, 2012). Given the overall abundance and co-localization of CYP3A4 and P-gp in GI 
tract and the liver, and their involvement in pre-systemic/first pass drug clearance, potential 
changes in the expression and activity of these agents have a strong possibility of altering the 
oral bioavailability and pharmacokinetics of everolimus (van Waterschoot & Schinkel, 2011). 
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Figure 3: Proposed biotransformation pathways for everolimus - ring-opened hydrolysis 
product of everolimus at C-35 position (PKF229-255), seco acid of everolimus at C-35 
position (PKF226-320), hydroxylated metabolites of everolimus at C-24- and C-25 position 
(24-0H-RAD & 24-0H-everolimus), hydroxy metabolite of everolimus at C-46 position (46-
0H-RAD),  and a direct phosphatidylcholine conjugate of everolimus (not shown here).   
 
1.4 BEZ235 – PI3K/mTOR inhibitor 
1.4.1 First Dual Inhibitor of PI3K/mTORC1,C2 
BEZ235 is a novel imidazoquinoline derivative from Novartis oncology pipeline, 
which specifically inhibits PI3K and mTOR kinase activity by binding to the ATP binding cleft 
of these enzymes (Figure 2) (Figure 4) (Table 3) (Maira et al., 2008). BEZ235, which is 
38 
 
structurally different from other available lipid kinase inhibitors, was designed based on a 
structure activity based on previously identified dual PDK1/PI3K lead compound (Maira et al., 
2008). Docking studies with PI3Kα homology model suggest that the inhibitory effect of 
BEZ235 might be mediated through H-bond interaction with Val851 , Asp933 and Ser774 in the 
hinge region of the ATP-binding pocket of the p110α subunit of PI3K (Figure 5) (Maira et al., 
2008). Similarly, systematic docking of a homology model of mTOR suggested BEZ235 binds 
with the side chain of Ser2165 of the catalytic site of mTOR. Thus, BEZ235 is a pan-class I PI3K 
inhibitor and binds to the catalytic site of mTOR, inhibiting mTORC complexes, mTORCl and 
mTORC2 (Maira et al., 2008). 
 
Figure 4: Chemical structure of BEZ235 or NVP-BEZ235. A novel imidazoquinoline 
derivative, 2-Methyl-2-4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-1H-imidazo[4,5-
c]quinolin-1-yl]phenyl propanenitrile. 
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Figure 5: BEZ235 docked in the catalytic site of PI3Kα - result of systematic docking using 
energy minimization for all possible orientations including H-bond interactions of BEZ235 
in the PI3Kα ATP cleft   
From (Maira et al., 2008) , printed with permission from AACR 
BEZ235 is a potent inhibitor with the half-maximum inhibitory concentration (IC50) in 
nanomole range. IC50 for BEZ235 inhibition of p110 α, β, γ and δ, are 4, 75, 7 and 5 nmol/L, 
respectively and mTOR inhibition IC50 is 20.7 nmol/L (Table 3). BEZ235 is highly specific for 
class I PI3K, with no relevant inhibitory effect towards other receptor tyrosine kinases or other 
kinases mediating PI3K signaling (PDK1, PKB/Akt) and the IC50 values in each case were > 2.5 
μM. BEZ235 has a molecular weight of 469.54 g/mol with a logarithm of the octanol-buffer 
partition coefficient (log P) of 4.725 and a dissociation constant (pKa) of 6.4 (compound ID: 
CHEMBL1879463) (Maira et al., 2008). 
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Table 3: Biochemical profile of BEZ235 – Class I PI3Ks and mTOR inhibition 
 Enzyme IC50 (nmol/L)*
Class I PI3K p110α 4.0 ± 2 nM 
P110α-H1047R 4.6 ± 0.8 nM 
P110α-E545K 5.7 ± 1.0 nM 
p110β 75 ± 45 nM 
p110δ 7 ± 6 nM 
p110γ 5 ± 4 nM 
mTOR 20.7 nM 
 Panel of 18 other protein kinases >10,000 nM 
*data from (Maira et al., 2008) 
1.4.2 Preclinical Efficacy of BEZ235 
In preclinical studies, BEZ235 effectively inhibited tumor growth in various mouse 
xenograft models, including models of glioblastoma multiforme, breast cancer and prostate 
cancer (Cao, Maira, Garcia-Echeverria, & Hedley, 2009; Serra et al., 2008). Efficacy of BEZ235 
was evaluated in glioblastoma cell line (U87MG), PTEN-negative cell line, and PC3M prostate 
tumor cell line, and was observed to reduce S473P-Akt and T308P-Akt levels in a dose-
dependent manner (Figure 6) (Maira et al., 2008). BEZ235 was an effective inhibitor of PI3K 
with a potency 10 fold higher than wortmannin. In another study, BEZ235 blocked proliferation 
in a panel of 21 breast cancer cell lines of different origin and mutational status. BEZ235 
antiproliferative activity was superior to other rapamycin derivatives, which act as allosteric 
inhibitors of mTOR complex (Serra et al., 2008).  
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Figure 6: Effect of BEZ235 on downstream Akt and mTOR pathway. U87MG glioblastoma 
tumor cells were treated with the various inhibitors LY294002, Wortmannin, RAD001, 
ST1571 and BEZ235. The figure shows the Western blots for phosphorylated Akt (S473P 
and T308P), GSK3β, p70S6K, and FKHRL1. BEZ235 significantly reduced the 
phosphorylation levels of the mTOR activated kinase p70S6K and Akt downstream 
effectors, such as GSK3h and FKHRL1 
From (Maira et al., 2008) , printed with permission from AACR 
In preclinical studies, oral doses of BEZ235 between 25 - 50 mg/kg effectively 
inhibited growth of tumors in various mouse xenograft models, including models of glioblastoma 
multiforme (U87MGPTEN-/-), breast cancer (BT474HER2+, MDA-MB231HER2), and prostate cancer 
(PCM3PTEN-/-). At these dose ranges BEZ235 was well tolerated leading to no significant weight 
loss of the animals (Awasthi, Yen, Schwarz, & Schwarz, 2012). These studies demonstrated that 
BEZ235 has strong anti-proliferative activity against tumor xenografts that have abnormal PI3K 
signaling, including loss of PTEN function or gain of function PI3K mutations. 
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1.4.3 Preclinical Pharmacokinetics of BEZ235 
Preliminary in vitro and preclinical studies indicate that BEZ235 has adequate 
pharmacokinetic properties to be clinically viable. It was observed to have a good oral 
bioavailability albeit with high inter-species variability. Accordingly, oral bioavailability was 
50% in rat and 18% in dogs. Plasma Tmax was highly variable and was delayed to 24 hours, 
probably due to the poor solubility of the free base resulting in absorption in the distal part of the 
gastro-intestinal tract. The plasma protein binding of BEZ235 was high ~98%. Across all the 
species, metabolism of BEZ235 was slow with low turnover in rat, dog, monkey and human liver 
microsomes and slices. The metabolites identified were the result of oxygenation, N-
demethylation and conjugates of glucuronic acid. Mono-oxygenated BEZ235 was identified as 
major metabolite in human liver slices.  Plasma clearance of BEZ235 was 1.4 L/h/kg in rats and 
2 L/h/kg in dogs, the elimination half-life was 2 hr and 4.3 hr in rat and dog, respectively. The 
major route of BEZ235 elimination appears to entail biliary excretion in bile and feces, with 
approximately 27% eliminated unchanged in rats.  
1.5 Combination of BEZ235 and Everolimus 
1.5.1 Preclinical Studies - Synergism in the Combination 
Although, everolimus has shown encouraging results in renal cancer and improved the 
overall survival among patients with metastatic RCC, it has failed as single agent to show 
antitumor activity in other cancers (Bracarda et al., 2012). Everolimus treatment led to partial 
response by delaying tumor progression; however, there were no complete responses (Koh et al., 
2013). This can be due to two possible reasons: (1) incomplete inhibition of mTORC1 
downstream signaling. Everolimus in some cells prevents phosphorylation of S6K1 but not 4E-
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BP1, thus allowing the cells to escape growth inhibition and (2) it is ineffective against 
mTORC2, thereby inducing feedback activation of survival signaling pathways (Thomas et al., 
2012). To overcome the feedback activation, dual inhibitors of PI3K/mTOR such as BEZ235 
have been under investigation. At the University of Cincinnati, Drs. Sara Kozma and George 
Thomas research team recently evaluated the combination of BEZ235 with everolimus on HCC 
progression and observed that the two drugs acted synergistically in inhibiting the proliferation 
of cultured HCC cells. Diethylnitrosamine (DEN)-induced HCC model in mice which best 
represented the gene expression profile in human HCC was used to evaluate the efficacy of 
BEZ235 and everolimus alone and in combination. DEN-induced tumor bearing mice were 
treated for 28 days with everolimus (10 mg/kg) or BEZ235 (30 mg/kg), or a combination of 
everolimus (2.5 mg/kg) and BEZ235 (18 mg/kg). MRI analysis of the tumor volume scans from 
days 0 and 28 revealed a significant treatment effect of the combination of low doses of 
everolimus and BEZ235 resulting in a 39% regression in the tumor volume (Figure 7) (Thomas 
et al., 2012). Interestingly, the combination of low dose of BEZ235 and everolimus induced a 
substantial effect on HCC regression, relative to mice treated with either drugs alone. 
Furthermore, gene expression analysis using microarray revealed that the combination 
of drugs induced autophagy and a significant number of genes reverting to baseline expression of 
normal liver. There were 5665 genes that were significantly altered compared to placebo 
treatment and a number of genes were observed to be reverted to roughly baseline expression 
levels expression. The following Venn diagram shows the number of genes reverting to normal 
levels in everolimus alone (195), BEZ235 alone (115), and in combination there were 475 genes 
(Figure 8) (Thomas et al., 2012).  Moreover, there were 354 unique genes, which were affected 
by combination treatment and not individual drug alone, suggesting that the effect of the 
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combination could not be recapitulated by increasing the dose of either drug alone. There was a 
significant downregulation of a number of autophagy genes, including Atg5 and Atg7, indicating 
BEZ235 and everolimus combination might induce autophagy in tumors. The underlying 
mechanism for synergism in two inhibitors acting on the same target is not clear and further 
studies exploring this are underway. This strong preclinical synergism in the combination led to 
an investigator initiated a Phase 1b-2 clinical trial to determine the safety, pharmacokinetics and 
pharmacodynamics of the combination of BEZ235 with everolimus in subjects with advanced 
solid tumors. 
 
Figure 7: Efficacy of BEZ235 and Everolimus alone and in combination. A) MRI scans of 
tumor volume in DEN-induced HCC mice from days 0 and 28 in placebo control, 
everolimus (10 mg/kg), BEZ235 (30 mg/kg), or a combination of everolimus (2.5 mg/kg) 
and BEZ235 (18 mg/kg). B) Fold change in tumor volume between days 0 and 28 based on 
quantification of the MRI scans.  (***P < 0.0001 based on Kruskal-Wallis test followed by 
Dunn’s multiple comparisons test.) 
From (Thomas et al., 2012). Reprinted with permission from AAAS. 
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Independent groups have reported the synergism in the combination of BEZ235 and 
everolimus. For instance, Xu et. al, studied the combination of sub-optimal concentrations of 
everolimus and BEZ235 and showed they exerted synergistic inhibition of the growth of human 
lung cancer (Xu et al., 2011). They demonstrated that the synergism in the combination of 
BEZ235 and everolimus might be through its effect on cap-dependent inhibition of eIF4E 
assembly reducing the expression of oncogenic proteins c-Myc and cyclin D1 (Xu et al., 2011).   
 
Figure 8: Gene expression analysis of tumors after treatment with BEZ235 and Everolimus 
alone and in combination. A) Venn diagram showing the number of genes reverting to 
normal expression level with everolimus and/or BEZ235 B) Heat map showing 
renormalized genes based on fourfold change compared to placebo 
From (Thomas et al., 2012). Reprinted with permission from AAAS. 
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1.5.2 Potential for Drug Drug Interaction 
A number of clinical trials investigating the potential drug-drug interactions of 
everolimus have been documented. In summary, everolimus is a substrate of CYP3A4 and p-
glycoprotein (p-gp). Everolimus is very sensitive to hepatic impairment and any changes in the 
CYP3A level (Kovarik, Beyer, Bizot, Jiang, Allison, et al., 2005; Kovarik, Beyer, et al., 2005a, 
2005b; Kovarik, Beyer, & Schmouder, 2006; Kovarik et al., 2002).  A CYP3A enzyme induction 
by rifampin 600 mg daily for 8 days increased the mean everolimus clearance by 172% with 
mean Cmax and AUC0-24 decreasing 58% and 63%, respectively. The mean t1/2 was significantly 
reduced from 32 hr to 24 hr (Kovarik et al., 2002). The impact of various CYP3A4 inhibitors on 
everolimus pharmacokinetics has also been evaluated.  In the presence of a strong inhibitor such 
as ketoconazole a huge increase (15 fold) AUC was observed.  With erythromycin and 
verapamil, two relatively moderate CYP3A4 inhibitors, the AUC increased  by 4.4 and 3.5 fold, 
respectively (Kovarik, Beyer, et al., 2005a).  Given this susceptibility of everolimus to 
modulation of CYP3A4 activity and its narrow therapeutic index, FDA labeling recommends 
therapeutic drug monitoring (TDM) for everolimus when co-administered with CYP3A4 and/or 
P-gp inducers or inhibitors. Interestingly, preliminary in-vitro metabolism data suggests that 
BEZ235 may modulate CYP3A4 activity and/or expression.  In the UC clinical study, BEZ235 
and everolimus were to be concurrently administered by the oral route, significantly increasing 
the possibility of high local (GI) concentrations of the two compounds and ensuing presystemic 
and first-pass drug-drug interactions.  Such interactions can influence both the fraction of the 
drug absorbed from the gut, Fg, and/or the fraction of the drug escaping the liver (Fh). We 
hypothesize that BEZ235 and everolimus could interact due to pharmacokinetic (absorption, 
metabolism) and pharmacodynamic pathways. 
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1.6 Pharmacokinetic Variability of Anticancer Agents 
Pharmacokinetics, the study of the time course of absorption, distribution, metabolism, 
and excretion, is critical in safe and effective therapeutic management of anticancer drugs. Most 
anticancer agents have a narrow therapeutic index and also exhibit a wide interindividual 
variability in the exposure impeding optimal clinical outcome. Systemic exposure after standard 
recommended doses of anticancer drugs has been reported to vary between 2–10 fold in patients. 
Pharmacokinetic parameters are correlated with treatment outcomes such as efficacy and 
toxicity, consequently, high pharmacokinetic variability can leads to increased risks of both 
toxicity and sub therapeutic dosing in the individual patient. Some of the potential sources of 
variation include interindividual differences in absorption, distribution, metabolism and 
excretion of anticancer drugs, physiological factors including age, gender, disease state and 
organ dysfunction, and interactions due to concomitant drug or food. The following section 
highlights some of these sources of variability in detail.  
1.6.1 Role of Drug Metabolizing Enzymes  
Drugs may be eliminated via chemical transformation involving a variety of enzymes 
through oxidation, reduction, and hydrolysis (phase I reactions) or glucuronidation, sulfation, 
acetylation, and methylation (phase II reactions). Biotransformation by drug metabolizing 
enzymes (DMEs) leads to more hydrophilic, polar entities, which are pharmacologically inactive 
and can be eliminated easily. Cytochrome P450 enzymes (CYP) is a collective name for a very 
large group of heme enzymes that have been conserved throughout nature since the beginning of 
life over 3.5 billion years ago (Nebert & Russell, 2002).  The CYPs have a very broad substrate 
specificity and it can range from small molecules (ethylene, MW = 28) to large molecules 
(cyclosporine, MW = 1201) (Testa & Kramer, 2007). Individual cytochrome P-450 enzymes are 
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classified by their amino acid similarities and are designated by a family number, a subfamily 
letter, a number for an individual enzyme within the subfamily. Currently there are over 57 
CYPs identified in humans, however, only a relatively few CYPs, mainly in the CYP1, CYP2, 
and CYP3 families, contribute to the metabolism of drugs. CYP enzymes are found in almost all 
tissues, including the intestine, lung, kidney, brain, adrenal glands, gonads, heart, nasal and 
tracheal mucosa, and skin, whereas the highest abundance of individual CYP enzymes isoforms 
is present in the liver. CYP enzymes comprise approximately 2% of total microsomal protein 
(0.3–0.6 nmol of total CYP per mg of microsomal protein) in human liver (Paine et al., 2006). 
The content of CYP enzymes is much lower in other tissues. There exist large intra- and inter-
individual variations in the expression and activity of CYPs which has been reported to range 
between 20 fold in the case of CYP2E1 to almost 1000-fold in CYP2D6 (Shimada, Yamazaki, 
Mimura, Inui, & Guengerich, 1994). Multiple factors contribute to this variability, such as 
genetic polymorphism, non-genetic (disease, age, sex), and environmental factors (concomitant 
drugs, food, smoking). For some CYP enzymes, such as CYP2D6, CYP2C19 and CYP3A5 
genetic polymorphisms have been shown to be a major source of variability in drug 
pharmacokinetics and response (Zanger & Schwab, 2013).  
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Figure 9: Relative abundance of cytochrome P450 enzymes (CYP450) A) Liver and B) 
Small intestine  
Data for the plot was obtained from (Galetin & Houston, 2006; Paine, Schmiedlin-Ren, & Watkins, 1999) 
1.6.2 Role of Cytochrome P450 3A 
The CYP3A is the most abundant isoform and constitutes about 40% of hepatic levels 
and 80% of CYP protein in small intestinal epithelium, particularly in the apical region of mature 
enterocytes at the tip of the microvillus (Paine et al., 2006; Watkins, 1994; Zanger & Schwab, 
2013). Moreover, CYP3A subfamily members have large active sites resulting in substrate 
promiscuity and up to 50% of clinically used drugs are substrates for CYP3A subfamily 
members (Zanger & Schwab, 2013).  There are four CYP3A isoforms, 3A4, 3A5, 3A7, and 
3A43. The CYP3A4 is the major isoform, expression of the three minor isoforms, CYP3A5, 
CYP3A7, and CYP3A43 is generally lower. Numerous anticancer drugs including docetaxel, 
doxorubicin, erlotinib, etoposide, gefitinib, imatinib, paclitaxel, tamoxifen are metabolized 
majorly by CYP3A. Thus, it is not surprising that interindividual variability in CYP3A activity 
has a major impact on the efficacy and safety/tolerability of anticancer drugs. The activity of 
CYP3A enzymes shows marked variability across patients (almost 5 fold) however, it is 
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observed to be continuous and unimodal. For CYP3A4 though there is a significant phenotypic 
variability there are no major functionally genotypic alleles found at an allele frequency higher 
than 0.1%. On the other hand, CYP3A5 gene is highly polymorphic and genetic polymorphisms 
CYP3A5*3, CYP3A5*6 and CYP3A5*7 are frequently observed to impact the pharmacokinetics 
of drug (Weinshilboum, 2003). The most frequently observed variant allele is CYP3A5*3, the 
estimated allele frequency in different ethnic groups as follows: Caucasian populations, 0.82-
0.95; African American, 0.33; Japanese, 0.85; Chinese, 0.65; and Mexicans, 0.75 (Hustert et al., 
2001; Roy et al., 2005). 
Sirolimus, an mTOR inhibitor, is a substrate of CYP3A5 and its oral clearance was 
significantly decreased in patients who were homozygous for the CYP3A5*3 allele. Patients 
with CYP3A5*1/*1 and *1/*3 genotypes required a significantly higher sirolimus daily dose to 
achieve the same blood concentration as compared to patients with *3/*3 (Le Meur et al., 2006; 
Renders et al., 2007). Anticancer drugs such as docetaxel and gefitinib, which are majorly 
metabolized by CYP3A4, have been reported to show a variable response possibly related to the 
high interindividual variability in the activity of CYP3A4. Using midazolam oral clearance or 
erythromycin breath test as a marker for hepatic and gut CYP3A4 level, authors could correlate 
the incidence of greater toxicity in patients with the lowest CYP3A4 activity resulting in very 
high exposure of these drugs (Hirth et al., 2000; J. Li et al., 2006).  
1.6.3 Modulation of CYP3A – Inhibition, Induction 
The expression and enzymatic activity of CYP3A can be modulated by inhibition 
and/or induction. The inhibition of CYP3A, categorized as reversible, quasi-irreversible or 
irreversible, could result in decreased metabolism of a drug leading to unexpected elevations in 
the plasma concentrations ultimately resulting in a variety of minor as well as serious adverse 
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effects (Huang et al., 2008) . Reversible inhibitors compete for the active catalytic site of CYP 
causing a transient reduction in the metabolic activity, which is restored upon removal of the 
inhibitor. On the other hand, mechanism-based inhibitors can inhibit CYP enzymes in an 
irreversible or quasi-irreversible manor by binding covalently to the prosthetic heme. These 
mechanism-based inhibitors are often characterized, as time-, concentration- and NADPH-
dependent enzyme inactivation and the loss of CYP activity are more pronounced and persistent, 
as they require synthesis of new enzyme for restoring normal enzyme function (Galetin, Burt, 
Gibbons, & Houston, 2006; Zhou & Zhou, 2009). Further, mechanism-based inhibition can lead 
to clinically relevant drug-drug interactions or non-linear pharmacokinetics of a drug. 
Ketoconazole, an antifungal agent, is a potent reversible competitive inhibitor of CYP3A and has 
been reported to increase the exposure of CYP3A4 substrates, some “sensitive substrates” such 
as simvastatin and lovastatin exposure were increased 5 fold upon administration with 
ketoconazole (Ogasawara et al., 2009).  
1.6.4 Significance of DDI - Variability  
Furthermore, significant inter-individual variability has been reported in drug-drug and 
food-drug interactions due to CYP3A inhibition (Shimada et al., 1994; Wilkinson, 2005). There 
was a 37.5 fold decrease in terfenadine clearance when dosed with ketoconazole, which cause a 
potentially fatal DDI, QT interval prolongation or torsades de pointes (Honig et al., 1993). 
Notably, there was a significant inter-individual variability in this interaction, which ranged 
between 16 – 73 folds. (Honig et al., 1993). Another significant interaction is reported in the case 
of statins (simvastatin, cerivastatin, atorvastatin, lovastatin) when co-administered with CYP3A4 
inhibitors causes severe rhabdomyolysis (Golomb & Evans, 2008). Similarly, in the case of 
selective estrogen receptor modulators, tamoxifen, which is activated to more potent 
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antioestrogenic metabolites through CYP enzymes such as CYP3A, CYP2D6, CYP2C9, 
CYP2C19, CYP2B6 and CYP1A2  (Jin et al., 2005). However, the key metabolites of tamoxifen, 
4-hydroxytamoxifen and endoxifen, are formed primarily by CYP2D6, and N-
desmethyltamoxifen is formed primarily by CYP3A4. Consequently, interindividual variability 
in the relative expression and activities of these CYP isoforms could affect the therapeutic 
outcome associated with tamoxifen therapy (Nowell et al., 2005). 
1.6.5 Role of Efflux Transporters 
Drug efflux transporters such as ATP-binding cassette (ABC) family of transporters 
and solute carrier (SLC) transporter families play a major role in contributing to the disposition 
and the prevalent inter-individual variability in anticancer drugs. Drug efflux transporters such as 
P-glycoprotein (P-gp), multidrug resistance protein 2 (MRP2), and breast cancer resistance 
protein (BCRP) are located at the apical membrane of intestinal epithelium and function as efflux 
pump limiting the absorption into the systemic circulation. On the other hand, drug efflux 
transporters at the apical membrane of hepatocytes and renal tubular cells pump drugs and 
metabolites into bile and urine, respectively, resulting in enhanced excretion of drugs thus 
facilitate drug elimination (Giacomini et al., 2010).  Moreover, they are frequently found to be 
overexpressed in cancer cells and contribute to intrinsic or acquired resistance to MTAs and 
diverse cytotoxic agents (Gottesman, Fojo, & Bates, 2002).  Similar to the concerns with 
modulation of CYP enzymes, perturbation of the activity and/or expression of drug transporting 
proteins contribute to DDIs.  Co-administration of drugs that bind to the active sites on these 
transporters may cause a direct/competitive inhibition of the transporter activity.  Xenobiotics, 
including drugs may also upregulate or down regulate the expression of transporters resulting in 
altered pharmacokinetics of other co-administered.  Two other major concerns associated with 
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drug transporters include marked inter-subject variability and their contribution to organ specific 
toxicity (Endres, Hsiao, Chung, & Unadkat, 2006).  Perhaps more pertinent to our study, 
CYP3A4 and P-gp have an overlapping substrate specificity and both are frequently co-localized 
near the apical membrane of intestinal epithelium (Cummins, Jacobsen, & Benet, 2002; van 
Waterschoot & Schinkel, 2011), and contribute in a concerted fashion to drug disposition. It has 
been hypothesized that for many drugs, the interplay of CYP3A4 and P-gp increases efficiency 
of intestinal first-pass metabolism of orally administered drugs as a result of a potentially 
synergistic collaboration. However, in liver, orally administered drugs would first encounter 
(upon uptake into the liver) intracellular CYP3A, before being potentially transported into the 
bile by P-gp (Cummins et al., 2002). 
1.7 Mechanistic Physiologically Based Pharmacokinetic (PBPK) Models to Predict 
Interaction 
In oncology, about 20-30% of all adverse events have been associated with DDI’s that 
lead to significant changes in blood drug or tissue concentrations. Early identification of the 
mechanism of this interaction can be utilized to quantitatively predict and design clinical trials 
that maximize the benefit of the combination. Mechanistic pharmacokinetic models are useful 
tools in the study of complex systems such as the liver, intestine and its role in drug disposition 
and interaction (Kostewicz et al., 2014). The models have been shown to be critical tools and 
positively affect the costs and timeline for drug development. While the static model uses a 
conservatory approach by predicting the interaction at the maximum inhibitor concentration, the 
dynamic PBPK modeling uses a more pragmatic time varying concentrations of the inhibitor in 
various tissue compartments for modeling. These models are typically developed as a set of 
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mathematical equations that describe the processes underlying the behavior of the system being 
modeled. 
1.7.1 Static Equations for Studying Metabolism and Transporter Based Drug Drug 
Interaction 
Inhibition of the metabolism of one drug (i.e., substrate) by the addition of another 
(i.e., inhibitor) can result in a change in systemic exposure of the substrate and may lead to 
serious toxicities. In a drug-drug interaction clinical trial, substrate drug concentration profiles 
are determined in the presence and absence of an inhibitor. The pharmacokinetic consequence of 
drug-drug interaction is quantified by the change in overall systemic exposure (i.e., area under 
the concentration vs. time curve, AUC) of the substrate drug. The primary end point used in a 
drug-drug interaction clinical trial is the AUC ratio (AUCR) or the fold change in AUC of the 
substrate drug in the presence to in the absence of an inhibitor. Input parameters include a 
number of in vitro and in vivo pharmacokinetic parameters of substrate and inhibitor. 
1.7.2  Dynamic Physiologically Based Pharmacokinetic (PBPK) Models  
PBPK models describe drug disposition within the body using a more realistic 
physiological compartmental system (Rowland, Peck, & Tucker, 2011). These compartments 
typically represent anatomical body tissues and organs that integrate system specific properties 
(e.g. blood flow, organ mass) along with drug properties (e.g. binding affinities, permeability) 
with a structural model reflecting the anatomical arrangement. In contrast to the static models, 
PBPK model incorporates time-varying inhibitor concentration. Consequently, the parameters of 
a PBPK model include a drug-independent subset (e.g., blood flow and tissue volume), whereas 
an empirical pharmacokinetic model structure is solely dependent upon the observed data set. 
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2 Hypothesis and Specific Aims 
As indicated earlier, PI3K pathway is an important signal transduction oncogenic 
driver dysregulated in numerous solid tumors.  Given its critical role and inter-play with other 
mTOR pathway, considerable efforts have been made to develop compounds that target both 
pathways.  BEZ235 is the first generation of such dual PI3K/mTOR inhibitors (Maira et al., 
2008; Serra et al., 2008).  Furthermore, the combination of this agent with potent mTOR 
antagonist, everolimus, may potentially act synergistically in suppressing cell growth.  Indeed, 
combination of BEZ235 and everolimus was observed to exert such synergistic effects against 
hepatocellular carcinoma in vitro and in a DEN-induced HCC mouse model (Thomas et al., 
2012). Based on these exciting findings an investigator-initiated Phase I study combining 
BEZ235 and everolimus was initiated in the UC Cancer center to evaluate safety, tolerability, 
efficacy and pharmacokinetics in patients with solid tumors.   Everolimus, which is exclusively 
metabolized by CYP3A4, has been reported to be susceptible to modulation 
(induction/inhibition) of CYP3A4 by other drugs (Kovarik et al., 2006). Everolimus exposure 
has a strong correlation with its efficacy as well as toxicity, requiring therapeutic monitoring 
when given along with modulators of CYP3A4 (Lorber et al., 2005; Starling et al., 2004). On the 
other hand, in vitro studies show that BEZ235 has a potential to modulate CYP3A4. Thus, the 
overall hypothesis of this study is that BEZ235 has a potential to alter the metabolism and/or 
transport of everolimus that may result in changes in the clinical pharmacokinetics of 
everolimus.  To test this hypothesis we propose to pursue the following specific aims:  
1. To evaluate the clinical pharmacokinetics of BEZ235 and everolimus in a Phase 
1b-2 study and perform a population based pharmacokinetic modeling to discern any potential 
pharmacokinetic interaction of the combination of BEZ235 and everolimus.  
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The primary objective of this aim was to characterize the pharmacokinetics of BEZ235 
and everolimus in cancer patients enrolled in the study. We developed and validated a sensitive 
and selective bioanalytical method using a liquid chromatography tandem mass spectroscopy 
(LC/MS/MS) method for the analysis of BEZ235 and everolimus. Pharmacokinetic analysis was 
performed to estimate single dose and steady state pharmacokinetic parameters of BEZ235 using 
non-compartmental analysis and dose proportionality was investigated.   Similarly, everolimus 
pharmacokinetic parameters after single dose and steady state were estimated using non-
compartmental analysis and population pharmacokinetic modeling approach.  In addition, the 
potential impact of everolimus pharmacokinetics when administered along with BEZ235 was 
evaluated using non-compartmental and population pharmacokinetic approach. 
2. To gain insights into the potential pharmacokinetic interaction of BEZ235 and 
everolimus employing in vitro tools.   
We investigated the metabolism based DDI using human liver microsomes, as well as 
using primary human hepatocytes. Competitive and time dependent inhibition potential of 
BEZ235 was investigated along with its CYP3A4 induction potential. Mechanism of time-
dependent inhibition of CYP3A4 by BEZ235 was investigated using human liver microsomes. 
Further, the role of P-gp or MDR1 efflux transporter based interaction of BEZ235 and 
everolimus was evaluated using in vitro cell culture models using Caco-2 (human colon 
adenocarcinoma).  
3. To establish a mechanistic physiology based pharmacokinetic model (PBPK) to 
predict and study the pharmacokinetic interaction between BEZ235 and everolimus.  
A mechanistic PBPK model was employed to predict the extent of interaction and the 
resulting alteration in clinical pharmacokinetics of everolimus using in vitro data. The modeling 
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was used to gain insights into the probable mechanism of interaction, critical parameters 
contributing to the impact and variability of interaction. In addition, a parameter sensitivity 
analysis was performed to access the influence of system specific as well as drug specific 
parameters, contributing to the interaction. Stochastic simulation studies were implemented to 
guide clinical dose optimization.   
The primary goal of this study was to evaluate the pharmacokinetics of BEZ235 and 
everolimus in Phase Ib study. In addition, we delineated the postulated DDI with a focus on 
quantitative assessment of changes in the single dose and steady state pharmacokinetics and to 
gain an understanding of the mechanistic basis of the interactions. Consequently, we intended to 
use that information to facilitate the dose optimization of not only the first generation 
PI3K/mTOR inhibitor, BEZ235, with other drugs and adjuvants.  Our results would also have 
implications for novel formulations of this agent and other drugs in class in developmental 
stages, which has shown promising in vitro results. Understanding of absorption, distribution, 
metabolism and excretion processes provides a framework to simulate and predict drug exposure 
and activity for the combination of BEZ235 and everolimus.  
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3 Aim 1: Clinical Pharmacokinetics of BEZ235 and Everolimus in Phase 1b-
2 Study  
3.1 Phase 1b Study Design 
The study was an open-label, single center, dose-escalation trial assessing the safety 
and tolerability of the combination of BEZ235 and everolimus. The primary objectives of the 
study were to determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) 
of this combination in patients with solid tumors. The secondary objectives were to characterize 
the pharmacokinetics of BEZ235 and everolimus in combination. The starting dose was 2.5 mg 
of everolimus and 200 mg for BEZ235 given once daily and further escalated as shown in Table 
4 until MTD. The MTD was the highest dose at which ≤ 33% of patients experience DLT during 
the first cycle of combination of everolimus and BEZ235. Toxicity was assessed utilizing the 
National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) 
v4.0. Patients self-administered and reported daily everolimus and BEZ235 dosing on a patient 
calendar. BEZ235 formulation was a special delivery system (SDS) in the form of a sachet. 
Patients consumed a light low fat meal 30 minutes prior to BEZ235 and everolimus dosing. 
Patients were treated until either unacceptable toxicity was reached or until disease progression.  
Table 4: Phase I dose escalation scheme 
Dose Level Everolimus (mg/day) BEZ235 (mg/day) 
1 2.5 200 
2 2.5 400 
3 2.5 800 
4 5 800 
5 5 1000 
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3.2 Patient Eligibility Criteria and Evaluation: 
The study was approved by Protocol Review Monitoring Committee of the UC Cancer 
Institute and the Investigational Review Board of the University of Cincinnati. The trial was 
conducted at the University of Cincinnati Cancer Institute in accordance with the International 
Conference on Harmonization (ICH)/ Good Clinical Practices (GCP) guidelines as well as the 
Declaration of Helsinki. The investigational agents BEZ235 and everolimus were supplied by 
Novartis Oncology (Hanover, NJ). Participants in these studies were male or female subjects 
aged ≥18 years with cytologically or histologically confirmed advanced or metastatic solid 
cancer that exhausted standard therapies were eligible for enrollment. At least one measurable 
lesion defined by RECIST 1.1 was required. Key inclusion criteria were Eastern Cooperative 
Oncology Group (ECOG) performance status ≤ 2, ability to understand and sign informed 
consent, and adequate bone marrow and organ function. Key exclusion criteria included previous 
treatment with PI3K inhibitors, concurrent or history of unrelated malignancy, current use of 
another investigational antineoplastic agent, currently receiving or had received anticancer 
therapy in the 4 weeks before enrollment, poorly controlled diabetes, chronic treatment with 
corticosteroids or other immunosuppressive agent, other serious disease that may impact 
survival, prolonged QT syndrome, abnormal gastrointestinal function resulting in poor BEZ235 
absorption, required treatment with other drugs that are known to be strong inhibitors or inducers 
of the isoenzyme CYP3A4, pregnancy or lactating patients, symptomatic CNS involvement, or 
uncontrolled infection.  
Patients were screened within two weeks of starting on study. After informed consent, 
baseline visit included general demography, medical history including medications, thorough 
physical exam, vital signs, ECOG performance status, ECG, blood collection for biochemistry, 
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lipase, fasting plasma glucose, C-peptide, hemoglobin A1c levels, INR, PT, hematology, 
urinalysis, pregnancy test (if applicable), cardiac imaging, CT of chest, abdomen and pelvis 
within 28 days, brain MRI (for brain tumors), pulmonary function testing (based on symptoms 
and history), and hepatitis screen. Tumor response was measured using imaging and RECIST 
criteria every 8 weeks. After discontinuation of study medication, an end of study visit was 
performed at 30 days. 
3.3 Safety Measures 
Safety was evaluated by monitoring adverse events, hematology, blood chemistry 
profiles, and regular physical exams. Adverse events were graded using CTCAE v4.1(National 
Cancer Institute, May 29, 2009). Dose reductions and delays were allowed for significant drug-
associated toxicities of up to two weeks.  At least three patients were enrolled in each cohort and 
dose escalation was permitted once three patients were evaluable for DLT.  At each given dose 
level, there was a gap of one week between the inclusion of the first patient and next two 
patients. Assessment for DLT was conducted during the first 28 days after enrollment. The DLT 
was defined as Grade 4 neutropenia >7 days duration or febrile neutropenia, grade 4 
thrombocytopenia or grade 3 thrombocytopenia with bleeding, grade 3 or 4 non-hematologic 
toxicity, treatment delay ≥ 2 weeks due to unresolved toxicity, or any other non-hematologic 
toxicity grade 2 or higher that the investigator and medical monitor felt was dose limiting. If a 
patient developed a DLT, then 3 more patients were entered at that dose level. The MTD was the 
dose in which less than 1 patient developed a DLT. 
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3.4 Pharmacokinetic Assessments 
3.4.1 Pharmacokinetic Sampling  
Blood samples (10 ml) for pharmacokinetic analysis of BEZ235 and everolimus were 
obtained pre-dose and at 1, 2, 4, 6, 8, 10 and 24 h after dosing on days 1 and 28 (Figure 10). 
Additional blood samples were collected at 48 and 72 h after the last dose (day 28). For BEZ235 
pharmacokinetics, blood was collected into sodium heparin tubes and the plasma was separated. 
For everolimus pharmacokinetics, blood was collected into EDTA-containing tubes and stored at 
-20Ԩ until analysis. Whole blood was preferred for everolimus analysis as it is extensively 
distributed into erythrocytes with binding of 85% at clinically observed concentrations (Salm, 
Taylor, Lynch, & Pillans, 2002). 
  
 
Figure 10: Dosing and pharmacokinetic sampling schedule used in the UC Phase I trial: 
BEZ235 and everolimus were dosed once daily. Each treatment cycle consisted of 28 days 
with intense PK sampling on day 1 and 28.  
3.4.2 Bioanalytical Method for Quantification of BEZ235 and Everolimus 
3.4.2.1 Chemicals 
BEZ235 and everolimus were a gift from Novartis (Basel, Switzerland). NVP-
BBD130 was used as internal standard for BEZ235 and was purchased from Axon Medchem 
(Groningen, The Netherlands). Everolimus-d4 was used as internal standard for everolimus and 
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was purchased from TRC chemicals (Toronto, Canada). All other solvents and reagents were of 
the highest analytical grade supplied from Fisher Scientific (Fair Lawn, NJ). Drug-free human 
whole blood and plasma were obtained from healthy donors from Hoxworth Blood Center 
(Cincinnati, OH). 
3.4.2.2 Stock Solution and Calibration Standards  
Primary stock solution of BEZ235 and NVP-BBD130 were prepared by dissolving 1 
mg of each compound in 1ml of dimethyl sulfoxide (DMSO). This was further diluted in 
methanol to get spiking standard solutions. BEZ235 calibration standards with concentrations of 
5, 10, 25, 125, 250, 500, and 1000 ng/mL were prepared by spiking appropriate volume of 
spiking solution in blank plasma. Similarly, primary stock solution of everolimus and 
everolimus–d4 were prepared by dissolving 1 mg of each compound in 1ml of methanol. 
Everolimus calibration standards were prepared by spiking appropriate volume of spiking 
solution in drug-free whole blood and the final concentrations of 1, 5, 10, 25, 100, 250, 500, and 
1000 ng/mL. All stock solutions and plasma standards were stored at −20Ԩ until analysis. 
3.4.2.3 BEZ235 Bioanalysis: Sample Preparation and Chromatographic Conditions  
A reversed-phase high-performance liquid chromatography with fluorescence 
detection was used for quantification of BEZ235 (Lin, Chandrasekaran, de Gooijer, Beijnen, & 
van Tellingen, 2012). Chromatographic separations were performed on a Waters Sunfire™ C18 
column (2.1 mm × 150 mm). The chromatographic system consisted of Waters 1525 pump 
connected to Waters 717 plus autosampler and a Waters 474 fluorescence detector operating at 
excitation and emission wavelengths 270 and 425 nm, respectively. The mobile phase consisted 
of methanol: 10 mM ammonium acetate buffer adjusted to pH 3.7 (75:25, v/v). The mobile phase 
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was delivered at a flow rate of 0.6 ml/min. Sample Preparation consisted of liquid liquid 
extractions using ethyl acetate. To 200 µL of plasma (standard / sample) 50 µl of IS working 
solution and 1 ml ethyl acetate was added. After vigorously mixing for 1 min, the samples were 
centrifuged at 2000 RPM for 10 min to separate the aqueous and organic layers. The upper 
organic layer was separated into another clean tube and evaporated to dryness in a Speed-Vac set 
at 50 °C and the residue was reconstituted in 100 µl methanol–water (70:30, v/v). After 
vortexing the sample was transferred to an HPLC autosampler vial and a volume of 50 µl was 
injected into a HPLC system. 
3.4.2.4 Everolimus Bioanalysis: Sample Preparation and Chromatographic Conditions  
Everolimus concentrations were measured using a validated liquid chromatography 
coupled with mass spectrometer (LC-MS/MS) method. Chromatographic separations were 
performed on a Waters Symmetry™ C18 column (2.1 mm × 100 mm) connected to a liquid 
chromatography Finnigan Surveyor pump equipped with a Finnigan Micro AS autosampler 
connected to a linear ion trap-Fourier Transform LTQ-FT™ mass spectrometer in collaboration 
with Dr. Larry Sallans at Mass Spectrometry Facility, University of Cincinnati. Sample 
preparation solution consisted of methanol: 0.1 M zinc sulfate (70:30, v/v) and internal standard 
at 20 ng/mL concentration. To 500 µL of whole blood (standard / sample) 2 ml of sample 
preparation solution was added and vigorously mixed for 1 min. The samples were centrifuged at 
2000 RPM for 10 min and the upper clean layer was separated and loaded on to Oasis HLB SPE 
cartridges preconditioned with 3 ml methanol and 3 ml water. Cartridges were washed with 3 mL 
water, 3 mL methanol: water (50:50, v/v) and 1 mL heptane. Samples were eluted using 1 mL of 
heptane: 2-propranol (50:50, v/v) and evaporated to dryness in a Speed-Vac set at 50 °C. The 
residue was reconstituted in 100 µl methanol–water (70:30, v/v).  
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3.5 Pharmacokinetic Analysis 
3.5.1 Single Dose and Steady State Pharmacokinetics of BEZ235 and Everolimus 
3.5.1.1 Non-compartmental analysis 
Non-compartmental analysis using Phoenix WinNonlin 6.3 (Pharsight, Mountain 
View, CA) was performed to determine pharmacokinetic parameters of BEZ235 and everolimus 
on day 1 and day 28. Primary pharmacokinetic parameters including area under the plasma 
concentration-time curve from zero to last measurable time point (AUC0-24), maximum plasma 
concentration (Cmax), time to achieve the peak concentrations (Tmax), terminal elimination half-
life (t1/2) and oral clearance (CL/F) were calculated. The elimination half-life (t1/2) was calculated 
as 0.693/λz, where λz is the terminal-phase elimination rate constant. AUC0-24 was calculated 
using the linear trapezoidal rule area under the concentration time curve from time zero to 24 
hours. Accumulation index was calculated as ratio of systemic exposure parameters, AUC0-24, on 
day 28 over day 1.  
3.5.1.2 Dose Proportionality in BEZ235 Pharmacokinetics  
Since clinical pharmacokinetics of BEZ235 have not been published hitherto, it was 
important to assess a correlation between the BEZ235 dose and the resulting systemic exposure. 
Dose proportionality was assessed using the power model Y = α.(dose)β, where Y is the response 
variable (Cmax and AUC0-24), α is the expected value of Y at a reference dose, and β is the 
exponent used for examining the proportionality (Smith et al., 2000). The 90% confidence 
interval (CI) for β is calculated and compared with the dose-proportional limits of 
bioequivalence 0.8 - 1.25. Additionally, linear regression of systemic exposure (AUC0-24 and 
Cmax ) or systemic clearance to BEZ235 dose was performed.  
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3.5.2 Evaluation of Drug Interaction in Everolimus Pharmacokinetics 
3.5.2.1 Non-compartmental Analysis 
In order to evaluate the postulated impact of BEZ235 on everolimus pharmacokinetics, 
the single dose and steady state systemic exposure of everolimus (Cmax and AUC0-24) and CL/F 
derived from our study were compared to those previously reported. Everolimus 
pharmacokinetics in cancer patients at doses 5 mg and 10 mg once daily has been reported in the 
clinical pharmacology and biopharmaceutics review of Afinitor NDA, obtained from FDA (US-
FDA - clinical pharmacology and biopharmaceutics review).  Statistical analysis (Wilcoxon 
signed rank test, at 0.05 significance) was performed to test if there was a significant change in 
primary pharmacokinetic parameters of everolimus from day 1 to day 28. 
3.5.2.2 Population Based Analysis 
We also employed a population pharmacokinetic modeling using NONMEM 7.2 (Icon 
Development Solutions, MD, USA) which facilitates a non-linear fixed-effect modeling to 
further strengthen this comparison. The first-order conditional estimation (FOCE) method with 
interaction between inter-subject variability and residual variability was used  throughout the 
model-building process. The influence of patient’s age, weight, height, gender, body mass index 
and serum creatinine were evaluated as potential covariates. The selection of covariates and 
model was made based on the decrease in objective function (–2 log likelihood) of 3.84 points (p 
< 0.05) for a factor to be considered statistically significant. Model diagnostics consisted of 
goodness-of-fit plots, residuals plots including conditional weighted residuals (CWRES) vs. time 
and CWRES vs. PRED were used. Analysis of results and post processing were performed using 
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PsN, Xpose and R (Jonsson & Karlsson, 1999; Lindbom, Ribbing, & Jonsson, 2004; R 
Development Core Team, 2013).  
3.5.2.3 Pharmacogenomics - CYP3A and PXR Genotypes 
A single blood sample (10 ml) was collected in EDTA tubes from each subject for 
genotyping polymorphisms in CYP3A4, CYP3A5 and PXR (Table 5).  Genomic DNA was 
extracted and purified from whole blood samples using Gentra® Puregene® Kit, as per 
manufacturer’s instructions. The isolated DNA sample was quantitated using the NanoDrop® 
spectrophotometer (NanoDrop Technologies). The A260/A280 nm ratio calculated by the 
NanoDrop® spectrophotometer was used to evaluate the DNA purity. The ratio of A260/A280 was 
between 1.8 and 2.0 for all the samples. 
Real-time TaqMan® PCR was performed according to the manufacturer’s standard PCR 
protocol. Briefly, 50 ng total DNA was mixed TaqMan® Universal PCR Master Mix and 
TaqMan® Assay Mix to a final volume of 5 µl.  ABI PRISM 7900HT Sequence Detection 
System (Applied Biosystems, Foster City, CA) was used for allelic discrimination and 
determining the genotypes. Genotyping assays contain specific forward and reverse primers to 
amplify the polymorphic sequence of interest and reporter probes labeled with a quencher, a 
minor groove binder (MGB) and either labeled with VIC® dye (λex - 538 nm, λem 554 nm) or 
with FAM™ (6-carboxyfluorescein) dye (λex - 494 nm, λem 518 nm). Data is analyzed by cluster 
plot analysis by plotting signal of FAM™ dye on Y‐axis and VIC® dye signal on X‐axis. The 
association between genetic polymorphism and the observed variability in pharmacokinetic 
parameters of BEZ235 and everolimus was investigated. Further, influence of SNP’s on the 
interaction potential, especially in predicting the pharmacokinetic outliers was studied.   
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Table 5: Genotyping: Primer sequence for CYP3A5, PXR and CYP3A4 genes used in the 
study 
Gene SNP ID Context Sequence [VIC/FAM] 
CYP3A5 rs776746 ATGTGGTCCAAACAGGGAAGAGATA[T/C]TGAAAGACAA
AAGAGCTCTTTAAAG 
PXR rs1523127 AATAAGCTAATACTCCTGTCCTGAA[A/C]AAGGCAGCGGC
TCCTTGGTAAAGCT 
PXR rs3814055 GGTCATTTTTTGGCAATCCCAGGTT[C/T]TCTTTTCTACCT
GTTTGCTCAATCG 
PXR rs1523130 AATCCAGTATTTCACTTACTCTTTT[C/T]CTTTCCAATATC
CTCATGACATTCA 
PXR rs7643645 GAGACCCCAGCTCTGCTGGGACCAC[A/G]GGCCATTTTTC
TTCCCATGTTGTGA 
PXR rs2472677 TCAACTTTTTTGTGCCATATTTTTT[C/T]TGATTAAAAAAC
AAACAAACACAAA 
CYP3A4 rs2740574 TAAAATCTATTAAATCGCCTCTCTC[C/T]TGCCCTTGTCTC
TATGGCTGTCCTC 
 
Table 6: Real-time quantitative PCR conditions  
Stage Step Temp Time 
Hold Activate 95°C 10 min 
Cycling (50 cycles) Denature 92°C 15 sec 
Anneal/Extend 58°C 1 min 
  
 
3.6 Results 
3.6.1 Patient Characteristics  
A total of 34 patients were screened and 19 patients were enrolled and treated on 
study. Twelve patients were male and the median age for all patients was 56 years (range, 36-73 
years) (Table 7). Fifteen patients were white, three black and one hispanic, and they had a 
median ECOG performance status of 1 (range, 0-2). Patients had received a median of 3 (range, 
1-9) systemic treatments prior to enrollment. 
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The study was initially designed to include five cohorts, but due to early termination 
included only three (Figure 11). The study was terminated early due to exceeding the MTD in 
cohort 3. All 19 patients reported at least one adverse event, four patients developed a dose 
limiting toxicity requiring discontinuation of study drug and there was one patient death. Four 
additional patients withdrew consent, one patient was removed from study for non-compliance, 
and one had a prolonged delay in treatment due to toxicity requiring discontinuation.  Overall, 
there were 199 adverse events reported and 34 serious adverse events, of which 9 were unrelated 
to study medication (Table 8: Serious Adverse Events (Grade 3-5). The most common adverse 
events included fatigue, anorexia, nausea, diarrhea and mucositis (Table 9: Common Adverse 
Events). On laboratory evaluation, elevated liver enzymes and anemia were the most commonly 
recorded events. 
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Figure 11: Consort Diagram of Phase I trial of BEZ235 and everolimus 
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Table 7: Patient demographics of study participants 
Demographic or 
Patient 
Characteristic 
BEZ235 
200mg/d + 
2.5mg/d 
Everolimus 
(N = 4) 
BEZ235 
400mg/d + 
2.5mg/d 
Everolimus 
(N= 7) 
BEZ235 
800mg/d + 
2.5mg/d 
Everolimus 
(N= 8) 
Total 
(N = 19) 
Age (median, 
years) 
59 
(range 36-64) 
57 
(range 54-73) 
52 
(range 38-62) 
56 
Male 3 3 6 12 
Female 1 4 2 7 
ECOG PS=0 0 2 1 3 
ECOG PS=1 4 5 6 15 
ECOG PS=2 0 0 1 1 
White 3 6 6 15 
Black 1 1 1 3 
Hispanic 0 0 1 1 
# prior treatments 3.5 
(range 2-5) 
3 
(range 2-9) 
3.5 
(range 1-5) 
3 
(range 1-9) 
Days of treatment 
received 
56 
(range 18-56) 
19 
(range 6-56) 
15 
(range 5-46) 
24 
(range 5-56) 
Tumor Types 
NSCLC 1 1 0 2 
Brain tumor 1 1 1 3 
Colon carcinoma 1 1 1 3 
HCC 1 0 0 1 
Pancreatic Cancer 0 1 0 1 
Esophageal Cancer 0 1 1 2 
Laryngeal cancer 
(adenoid cystic) 
0 1 0 1 
Appendix cancer 0 1 0 1 
HNSCC 0 0 1 1 
Prostate cancer 0 0 1 1 
Ovarian cancer 0 0 1 1 
Rectal NET 0 0 1 1 
Endometrial 
Cancer 
0 0 1 1 
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Table 8: Serious Adverse Events (Grade 3-5) reported in the trial in cohort 1 (BEZ235 
200mg/d + 2.5mg/d Everolimus), cohort 2 (BEZ235 400mg/d + 2.5mg/d Everolimus) and 
cohort 3 (BEZ235 800mg/d + 2.5mg/d Everolimus) 
Toxicity Category Toxicity Cohort 1 Cohort 2 Cohort 3 
General Symptoms 
Fatigue  1 1 
Angioedema  1  
Dehydration  2  
Lab Abnormalities 
ALT Elevation   1 
AST Elevation 1 1* 2 
Alkaline phosphatase 
elevation  2* 1 
Elevated bilirubin  1*  
Tumor Lysis Syndrome   1 
Hypophosphatemia   1 
Anemia  2 1 
Neutropenia  1  
Thrombocytopenia   1 
Gastrointestinal 
Symptoms 
Mucositis  1 1 
Diarrhea  1 1 
Nausea/vomiting   1 
Hepatorenal Syndrome   1 
Infectious 
Complications 
Gram positive bacteremia   2* 
Pneumonia* 1   
Perforated Diverticulitis*   1 
Neurologic 
Symptoms 
Gait Imbalance*  1  
Hydrocephalus* 1   
Peripheral Neuropathy   1 
 *Due to disease progression rather than study medication 
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Table 9: Common Adverse Events reported in the trial 
Adverse Event (AE) BEZ235 200 
mg 
RAD001 2.5 
mg 
N (%) 
BEZ235 
400 mg 
RAD001 2.5 
mg 
N (%) 
BEZ235 800 
mg 
RAD001 2.5 
mg 
N (%) 
Total AE, N 
Any AE 4 (100) 7 (100) 8 (100) 19 
Fatigue 3 (75) 5 (71) 6 (75) 13 
Fever 0 (0) 2 (29) 2 (25) 4 
Dehydration 0 (0) 2 (29) 3 (38) 5 
Anorexia 1 (25) 6 (86) 2 (25) 9 
Arthralgias/back pain 0 (0) 1 (14) 5 (63) 6 
Thrombocytopenia 1 (25) 2 (29) 2 (25) 5 
Anemia 1 (25) 5 (71) 3 (38) 9 
AST elevation 2 (50) 5 (71) 5 (63) 12 
ALT elevation 1 (25) 1 (14) 4 (50) 6 
Alkaline phosphatase 
elevation 
0 (0) 3 (43) 2 (25) 5 
Hypokalemia 0 (0) 4 (57) 2 (25) 6 
Hyperglycemia 0 (0) 1 (14) 3 (38) 4 
Rash 1 (25) 0 (0) 3 (38) 4 
Abdominal pain 2 (50) 1 (14) 2 (25) 5 
Nausea 0 (0) 5 (71) 7 (88) 12 
Vomiting 0(0) 2 (29) 4 (50) 6 
Diarrhea 2 (50) 5 (71) 7 (88) 14 
Sore throat/mucositis 0 (0) 2 (29) 6 (75) 8 
Acute Renal Failure 0(0) 3 (43) 2 (25) 5 
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In cohort 1 (200 mg of BEZ235 and 2.5 mg everolimus), there were three serious 
adverse events, but only one with elevation in liver enzymes was deemed to be study drug 
related. Non-related serious adverse events included hydrocephalus in a patient with 
glioblastoma multiforme (GBM) and pneumonia requiring hospitalization. Otherwise, the first 
cohort of patients tolerated treatment well and all but one patient completed two full cycles. In 
cohort 2, the dose of BEZ235 was escalated to 400 mg while everolimus dose remained the 
same. A total of seven patients were treated in this cohort as 1 DLT was observed. There were 14 
serious adverse events with the majority encompassing laboratory abnormalities including 
elevated liver enzymes and anemia, as well as dehydration and fatigue. The DLT observed was 
due to angioedema and its relationship to the study drug could not be excluded. Gait imbalance 
was thought to be related to GBM rather than BEZ235. In this cohort, several patients developed 
nausea and diarrhea as well as mucositis. As mucositis is a known side effect of everolimus 
(Fouladi et al., 2007), the increased rates of mucositis with combined mTOR inhibitors was not 
unexpected. One case of diarrhea and one case of mucositis were related to infectious causes: 
clostridium difficile and herpes simplex virus, respectively. In Cohort 3, eight patients were 
treated at BEZ235 at 800 mg with 2.5 mg everolimus. Most patients in cohort 3 developed 
fatigue, mucositis, diarrhea and nausea and several patients required treatment delays or dose 
reduction due to drug toxicity. Seventeen serious adverse events were observed. Of the grade 3/4 
events, one patient developed diverticulitis and perforation resulting in sepsis, which was 
deemed to be unrelated to treatment, while another patient developed hyperuricemia and acute 
tumor lysis syndrome after five days of treatment, hepatorenal failure, and Gram-positive 
bacteremia which was thought to be related to treatment. Two other DLTs were observed: One 
due to a grade 3 peripheral neuropathy, and on retrospective review of laboratory findings, it was 
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determined that a previous patient had experienced a DLT due to grade 3 hypophosphatemia.  
Therefore, it was determined that MTD had been reached in the previous cohort (400mg of 
BEZ235 and 2.5mg of everolimus). Only four patients (21%) completed two full cycles of 
treatment and no patients began a third cycle, as all that were evaluable at the end of cycle 2 had 
progression of disease (POD).  The most common reasons for early termination was due to 
withdrawal of consent, toxicity leading to prolonged delay, or a DLT. 
3.6.2 Tumor Response 
A total of eleven patients were evaluable for response. One patient with astrocytoma 
had stable disease and no responses were observed. Although treatment was tolerated well in 
cohort one, all patients in both cohort one and two that were evaluable, developed progression of 
disease requiring discontinuation from the study. Interestingly, one patient with a rectal 
neuroendocrine tumor in cohort 3 had a transient clinical response at fifteen days; however, he 
developed grade 3 laboratory abnormalities requiring a delay in treatment. Unfortunately, during 
his delay in treatment, he rapidly progressed and re-initiation of medication was unsuccessful. 
Although, there was one confirmed SD and one patient who had an observed initial clinical 
response as above, the study was discontinued after cohort 3 due to intolerable adverse effects. 
3.6.3 BEZ235 Bioanalysis 
A sensitive and selective liquid chromatography with fluorescence detection was 
developed for quantification of BEZ235 extracted from human plasma. BBD130 was used as an 
internal standard and the separations were performed on a Sunfire™ C18 column by isocratic 
elution with a mobile phase which consisted of methanol, and 10 mM ammonium acetate buffer 
adjusted with acetic acid to pH 3.7 (75:25, v/v). Fluorescence detector was set at excitation and 
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emission wavelengths of 270 and 425 nm, respectively. Liquid–liquid extraction with tert-butyl 
methyl ether was used for extracting BEZ235 and internal standard. Representative 
chromatogram of extracted plasma standard of BEZ235 is shown in Figure 12.  
 
  
Figure 12: Overlay of representative chromatograms from blank plasma and extracted 
BEZ235 standards spiked in plasma. The retention time of BEZ235 was 9.8 mins and 
BBD130 (internal standard) eluted at 7.9 mins. 
 
3.6.4 Everolimus Bioanalysis 
A sensitive and selective liquid chromatography coupled with mass spectrometer 
method was developed for quantification of everolimus. The chromatographic separation was 
performed on a  2.1 x 100 mm XBridge-C18 3.5 µm column (Waters) using a Finnigan (Thermo) 
Surveyor MS Pump Plus (LC pump) with a Finnigan (Thermo) Micro AS autosampler. The 
mobile phase consisted of 17:83 (water:methanol) with 0.1% ammonium hydroxide at flow rate 
of 200 µl/min. Eluate were analyzed by a Thermo Scientific LTQ-FT a hybrid mass spectrometer 
consisting of a linear ion trap and a fourier transform ion cyclotron resonance mass spectrometer 
operated in a negative ion mode using standard electrospray ionization (ESI) source. Following 
scan sequence were used for data acquisition,   
Scan sequence as follows: (run 5 scan sequence as below then repeat sequence) 
In
te
rn
al
 S
ta
nd
ar
d 
- 7
.9
65
B
E
Z2
35
 - 
9.
87
8
m
V
-10.00
0.00
10.00
20.00
30.00
40.00
50.00
60.00
70.00
Minutes
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00 16.00 17.00 18.00 19.00 20.00 21.00 22.00 23.00
76 
 
1. FT-ICR scan at 100,000 resolving power (at m/z 400) from m/z 300 to m/z 2000  
2. Ion trap MS2 scan: parent = 956.57 and acquire 260 to 965; normalize collision energy = 
25; width = 2 
3. Ion trap MS2 scan: parent = 960.60 and acquire 260 to 970; normalize collision energy = 
25; width = 2 
4. Ion trap MS2 scan: parent = 477.78 and acquire 130 to 965; normalize collision energy = 
25; width = 2 
5. Ion trap MS2 scan: parent = 479.80 and acquire 130 to 970; normalize collision energy = 
25; width = 2 
For quantitation, MS2 transitions, 956 to 590 (i.e. use the area of the 590 product ion from the 
956 parent ion) for everolimus and 960 to 590 (i.e. use the area of the 590 product ion from the 
960 parent ion) for everolimus-d4. Representative chromatogram and MS2 for everolimus and 
everolimus-d4 are shown in Figure 13 and Figure 14. 
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Figure 13: Everolimus Chromatogram a) Everolimus 25 ng/ml b) Internal standard D4-
everolimus 20 ng/ml 
   
Figure 14: Tandem Mass Spectrometry: MS/MS transition of A) everolimus and B) 
everolimus-d4 
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3.6.5 Pharmacokinetics of BEZ235 
Plasma concentration-time profile data of BEZ235 at 200, 400 and 800 mg on day 1 
are shown in Figure 15, and the non-compartmental pharmacokinetic parameters are listed in 
Table 10. The peak plasma concentration of BEZ235 occurred approximately 3 hours after 
administration and the median Tmax values were 3.8 ±1.6, 2.5 ±0.9 and 2.6 ±0.8 hours at doses of 
200, 400 and 800 mg, respectively. There was a significant inter-individual variability in 
BEZ235 pharmacokinetics. The plasma concentration maximum Cmax (mean ±SE) increased in a 
dose proportional manner from 45.2 ±11.4, 101.8 ±22.4 and 243.0 ±52.7 ng/mL and the 
corresponding dose normalized Cmax was 0.2, 0.3 and 0.3 at 200, 400 and 800 mg BEZ235 doses, 
respectively. The AUC0-24 (mean ±SE) values were 433.4 ± 96, 741.3 ± 171.2 and 2081.5 ± 
666.2 hr*ng/mL for 200, 400 and 800 mg BEZ235 doses, respectively. The elimination half-life 
showed higher variability across doses with mean values of 3.2 hours at 200 mg, 8.6 hours at 400 
mg and 5.9 hours at 800 mg.  
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Dose proportionality in BEZ235 pharmacokinetics was established by linear 
regression analysis and by power model for systemic exposure parameters Cmax and AUC0-24 
with BEZ235 dose. The β slope parameter for power model for Cmax and AUC0-24 were 1.21 
and 1.13, respectively. Further, the linear regression of Cmax and AUC0-24 to BEZ235 dose 
was linear with R2 of 0.9973 with P = 0.0127 (for slope ≠ 0) for Cmax and R2 of 0.9833 with P 
= 0.013 (for slope ≠ 0) for AUC0-24 (Figure 16). Steady state pharmacokinetic parameters of 
BEZ235 are listed in Table 10. 
There was a significant accumulation in BEZ235 on day 28 as indicated by Cmax 
and AUC0-24. Accumulation index calculated as AUC0-24,day 28 / AUC0-24,day 1  was be 6.6 ±4.9, 
2.4 ±1.1, and 8.1 ± 5.0 at doses of 200, 400 and 800 mg, respectively. The steady state 
terminal half-life was estimated to be 19.2 ±2.5, 43.4 ±10.8, and 15 ±6.4 hours at doses of 
200, 400 and 800 mg, respectively. 
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3.6.6 Everolimus Pharmacokinetics and Drug Interaction 
Everolimus whole blood concentration time profile data at 2.5 mg/day are shown in 
Figure 17 and pharmacokinetic parameters are listed in Table 11. The Cmax on Day 1 was 
14.08 ±1.5 ng/mL and was observed at a Tmax of 4.3 ±1.2 hours. The apparent clearance was 
24.76 ±2.91 L/hr, which was close to the reported everolimus clearance of 21.3 L/hr and 27.3 
L/hr at 5 and 10 mg dosed alone. To investigate any impact of BEZ235 co-administration on 
everolimus pharmacokinetics, dose normalized AUC0-24 and Cmax observed on day 1 and day 
28 were compared with the reported values at 5 and 10 mg/day (US-FDA - clinical 
pharmacology and biopharmaceutics review). The AUC0-24 was 124.32 ± 12.7 ng*hr/mL on 
day 1 and increased to 218.8 ± 33.26 ng*hr/mL on day 28. Similarly, Cmax increased from 
14.08 ±1.5 ng/mL on day 1 to 31.68 ± 7.4 ng/mL on day 28. On the other hand, clearance of 
everolimus (CL/F) decreased from 24.76 ±2.91 L/h on day 1 to 13.41 ±2.31 L/hr on day 28. 
Dose normalized exposure and clearance values in this study were compared with everolimus 
pharmacokinetics from cancer patients as reported in the Afinitor® clinical pharmacology and 
biopharmaceutics review (US-FDA - clinical pharmacology and biopharmaceutics review). 
As shown in the Table 12, there was a significant increase in everolimus systemic exposure 
(Cmax and AUC0-24) and a corresponding decrease in everolimus clearance (CL/F) on day 28. 
Dose normalized Cmax of everolimus was 10.91 ng/mL when given along with BEZ235 
compared to 6.3 ng/mL when dosed alone. Similarly, there was a 1.7 fold increase in dose 
normalized AUC0-24 in the combination of everolimus and BEZ235 when compared to 
everolimus alone. Further, there was a statistically significant decrease in clearance (p-value = 
0.0156) from day 1 to day 28. Since there were only few subjects in each BEZ235 dose group, 
statistical analysis on influence of BEZ235 dose on everolimus exposure was not performed. 
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Figure 18, shows individual line plots of change in CL/F and AUC0-24 in different subjects 
from day 1 to day 28, further illustrating the potential drug-drug interaction, strongly 
suggesting a BEZ235 influence on everolimus pharmacokinetics. 
 
Figure 17: Blood Concentration Time Profile of Everolimus on Day 1 and Day 28 after 
2.5 mg/day dose. Individual patient concentrations (light blue), mean concentrations 
along with standard deviation (dark blue) 
 
Table 11: Summary of everolimus pharmacokinetic parameters on day 1 and day 28 
 
Pharmacokinetic Parameter 
(Mean ± SE) 
 
Everolimus Dose 
2.5 mg 
Day 1 Day 28 
AUC 0-24 (ng*hr/mL) 124.32 ±  12.72 218.8 ±  33.26* 
AUC 0-∞ (ng*hr/mL) 191.15 ±  33.72 693.76 ±  148.08 
Cmax  (ng/mL) 14.08 ±  1.5 31.68 ±  7.4 
Cmax / Dose (ng/mL/mg) 5.63 ±  0.6 12.67 ±  2.96 
Tmax (hr) 4.3 ±  1.2 1.3 ±  0.2* 
Terminal half-life (hr) 15.69 ±  2.33 47.64 ±  9.1* 
Apparent Clearance, CL/F (L/hr) 24.76 ±  2.91 13.41 ±  2.31* 
  * P < 0.05 
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Table 12: Dose normalized AUC0-24, Cmax and CL/F of everolimus on day 1 and day 
28(steady state) 
 Dose Normalized 
Cmax (ng/mL) 
Dose Normalized 
AUC0-24 (ng*h/mL) 
Clearance (L/h) 
 Everolimus 
5 mg * 
Everolimus 
10 mg * 
Everolimus 
 + BEZ235 
Everolimus 
5 mg * 
Everolimus 
10 mg * 
Everolimus 
+ BEZ235 
Everolimus 
5 mg * 
Everolimus 
10 mg * 
Everolimus 
+ BEZ235 
Day 
1 
6.48 6.91 5.11 34.6 29.6 45.04 21.4 27.3 24.76 
Day 
28 
6.3 5.97 10.91 51 53.6 81.06 20 19.05 13.41 
* Data from clinical pharmacology and biopharmaceutics review for everolimus (US-FDA - clinical pharmacology and 
biopharmaceutics review) 
 
Figure 18:  Plot of individual change in everolimus AUC0-24 and CL/F from day 1 to day 
28 
 
3.6.7 Population Based Pharmacokinetic Analysis of Drug Interaction 
The effect of BEZ235 on everolimus pharmacokinetics was assessed by comparing 
the observed everolimus concentrations with simulated concentrations from a reported 
population pharmacokinetic model of everolimus. The population pharmacokinetic 
parameters of everolimus were obtained from clinical pharmacology review, which was 
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developed using data from various Phase I, Ib and pivotal Phase III trials of everolimus at 
doses ranging from 5, 10 mg once daily and 15, 30 mg weekly regimens. There were a total of 
398 subjects with 1667 concentrations in the population pharmacokinetic model building. A 
two-compartment model of disposition best fitted the everolimus data and the final parameters 
including the inter-individual variability are reported in the Table 13. We employed 
everolimus data from 18 subjects who completed day 1 dosing (123 blood levels) and from 7 
subjects who also completed the day 28 cycle (60 blood levels). First approach based on the 
reported population pharmacokinetic parameters of everolimus including fixed effects 
(structural model parameters) and random effects (variance model parameters), everolimus 
concentrations were simulated for once daily 2.5 mg dose (Figure 19). There was no 
significant change in the everolimus exposure on day 1, as represented in the Figure 19, as 
most of the observed everolimus concentrations fell within 90% prediction interval. However, 
almost all patients had everolimus concentrations outside the 90% prediction interval on day 
28 indicating a significant change in the everolimus pharmacokinetics on day 28. Further, 
everolimus trough concentrations Cmin,ss , Cmax,ss and AUC0-24,ss estimated from the simulation 
were compared with the reported values at 5 and 10 mg and also from the current study. As 
shown in Table 14, the observed trough concentrations Cmin,ss , Cmax,ss and AUC0-24,ss when 
everolimus was co-administered with BEZ235 was significantly higher than the simulated 
concentrations at 2.5 mg/day and were close to the reported values at 5 mg/day everolimus. 
Subsequently, the population pharmacokinetic parameters of everolimus were estimated along 
with the inter-individual variability. The clearance of everolimus was estimated to be 11.0 
L/h, which was significantly lower than the reported clearance, and all other pharmacokinetic 
parameters were close to the reported values Table 13.  
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Table 13: Reported population pharmacokinetics parameters of everolimus 
Pharmacokinetic Parameters Reported population mean (inter-individual 
variability, %CV) 
Clearance, CL/F (L/h) 18.8 (48.8 %) 
Central Volume, V1  (L) 191 (47.2 %) 
Inter compartmental clearance, Q (L/h) 46.2 (36.3 %) 
Peripheral volume, V2  (L) 517 (51.5 %) 
First order absorption rate, ka (h-1) 6.07 
Error Proportional 0.283 
Error Additional 0.075 
 
 
 
Figure 19: Simulated concentration time profile of everolimus at 2.5 mg/day generated 
using reported population pharmacokinetic model. Mean Concentrations – Red; 90% 
Confidence Interval – Grey Shaded Area) and shown in Blue are the Observed 
Concentrations from the current 
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Table 14: Comparison of steady state exposure of everolimus alone and in the presence 
of BEZ235. Steady state everolimus Cmin,ss , Cmax,ss and AUC0-24,ss at 2.5 mg/day were 
estimated from simulation, at 5 and 10 mg/day were obtained from (US-FDA - clinical 
pharmacology and biopharmaceutics review), and compared with observed values from 
UC clinical trial of everolimus at 2.5 mg/day with BEZ235  
Everolimus 
Steady State PK 
Based on 
simulation 
at everolimus 
2.5 mg/day 
Reported at 
everolimus 5 
mg/day* 
Reported at 
everolimus 
10 mg/day* 
Observed in the UC 
clinical trial  
at everolimus 2.5 
mg/day along with 
BEZ235 
Trough levels 
on day 28, 
Cmin,ss 
Mean 3.47 5.40 13.20 5.62 
SD 1.79 1.80 7.90 2.42 
Concentration 
maximum, 
Cmax,ss 
Mean 14.28 32.00 61.00 31.68 
SD 4.42 9.00 17.00 19.57 
AUC0-24,SS 
Mean 154.43 238.00 514.00 218.80 
SD 77.57 77.00 231.00 88.00 
 
3.6.8 Pharmacogenomics - CYP3A and PXR Genotypes 
An exploratory analysis was conducted to examine the influence of 
pharmacogenomics on the inter-individual variability in the extent of interaction. There were 
only two patients (10.5 %) with a nonfunctional variant of CYP3A5 *3/*3 (rs776746) which 
has been reported to be correlated to lower clearance and increased accumulation of CYP3A 
substrates. The only single-nucleotide polymorphism that has been reported to considerably 
influences CYP3A4 expression and activity is the CYP3A4*1B (rs2740574), was not 
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observed in the subjects. The pregnane X receptor (PXR) polymorphisms, 131C→A 
(rs1523127) and 63396C→T (rs2472677) were observed to have an influence on the fold 
change of AUC0-24 of everolimus. However, there were insufficient subjects in each group and 
lacked statistical power to conclude any effect. 
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4 Aim 2: To Gain Insights into The Potential Pharmacokinetic Interaction 
of BEZ235 and Everolimus Employing In Vitro Tools 
4.1 Materials 
Pooled human liver microsomes (HLM) from 20 subjects and recombinant 
CYP3A4 (Supersomes™) were purchased from BD Biosciences (Woburn, MA). Primary 
human hepatocytes, isolated from lobes of liver from 2 separate donors, were provided by the 
Liver Tissue Procurement and Distribution System (Pittsburgh, PA), funded by National 
Institutes of Health (NIH) contract N01-DK-9-2310 (Table 15). BEZ235 was a gift from 
Novartis. Ritonavir was obtained from NIH AIDS Research & Reference Reagent Program. 
BBD130, Rifampin, NADPH, testosterone and 6β-hydroxytestosterone were purchased from 
Sigma-Aldrich (St. Louis, MO). All other solvents were of the highest analytical grade 
supplied from Fisher Scientific (Pittsburgh, PA). 
Table 15: Human Liver Donor Information 
Batch 
Number Date Received Age Sex Race Cause of death 
HH2012 Saturday, March 17, 2012 54 Male Caucasian Metastatic Colon Carcinoma 
HH2029 Wednesday, July 18, 2012 31 Female Caucasian - 
4.2 Analytical Method for Measurement of CYP3A4 Activity  
The propensity of BEZ235 to inhibit CYP3A4 activity was assessed using 
testosterone as a CYP3A4 probe substrate. The formation of 6β-hydroxytestosterone 
metabolite of testosterone was used as a marker for CYP3A4 activity of HLMs or primary 
human hepatocytes used in the study. Quantification of 6β-hydroxytestosterone concentration 
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was performed using validated HPLC method as described earlier (Nallani, Genter, & Desai, 
2001; Nallani et al., 2003). In brief, mobile phase consisted of 60:40 methanol/water at a flow 
rate of 1 ml/min through a Sunfire®C18 column (3.9 × 125 mm). A Waters 486 UV/VIS 
detector at a wavelength of 242 nm was used for the detection of 6β-hydroxytestosterone, and 
11 α-hydroxyprogesterone was used as an internal standard.   
4.3 Optimization of Reaction Conditions for Testosterone Metabolism 
The linearity of formation of 6β-hydroxytestosterone in HLM was established by 
incubating testosterone with varying incubation times (5-60 minutes) and microsomal protein 
concentrations (10 – 100 µg). The formation of 6β-hydroxytestosterone was found to be linear 
over a 30 min period. Thus based on this initial characterization, the optimized incubation 
conditions included a protein concentration of 25 µg and an incubation time of 10 minutes. 
Methanolic solution of testosterone (0-250 µM) in a glass vial was evaporated to dryness 
under a stream of nitrogen gas. The vials were preincubated with the NADPH regenerating 
system and 100 mM phosphate buffer for 5 minutes in a shaking water bath maintained at 
37Ԩ. The reaction was initiated by addition of microsomes, and the total reaction volume was 
100 μL. The reaction was terminated at 10 min by adding ice-cold methanol (200 µl), 
vortexed and centrifuged at 13000 rpm for 5 minutes.  Samples were analyzed for the 
formation of 6β hydroxy testosterone metabolite using a validated HPLC method. Control 
incubations with no protein, no NADPH and/or no substrate were performed concurrently. All 
the incubations were performed in duplicates.  
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4.4 Assessment of Modulation of CYP3A by BEZ235 
4.4.1 Competitive Inhibition of CYP3A4 
Effect of varying concentrations of BEZ235 (0.01, 0.1, 1, 2.5, 5, 10 and 25 µM) on 
the metabolism of testosterone (125 μM), a prototypical CYP3A4 probe substrate, was 
evaluated in HLM. Protein concentration was kept at 25 μg in 0.1 M phosphate buffer saline 
(pH-7.4) and 1 mM NADPH at 37°C, total reaction volume was 100 μL and metabolism was 
terminated at 10 min by adding ice-cold methanol. Samples were analyzed for the formation 
of 6β hydroxy testosterone metabolite using a validated HPLC method. Ketoconazole (0.01 to 
10 µM) was used as the positive control in these studies. In all the incubations organic solvent 
was kept below 0.1%. Data were analyzed using GraphPad Prism® to determine KI, the 
dissociation constant of the inhibitor binding to the enzyme, of competitive inhibition.  
4.4.2 Time Dependent Inhibition Studies 
To study the potential for BEZ235 to inhibit CYP3A4 in a time dependent manner 
was studied by two- step dilution method in HLM. Initially, primary reaction mixtures were 
prepared by pre incubating different concentrations of BEZ235 (1 to 25 μM) with 10 X HLM 
(250 μg) for 5 minutes at 37°C. The reaction was initiated by the addition of NADPH-
regenerating system. At designated times (0, 5, 10, 15, 30, 45 and 60 minutes), aliquots of 10 
μL of the primary reaction mixtures were diluted 10-fold into a secondary reaction mixture 
that contained 90 µL of 250 μM testosterone, 0.1 M phosphate buffer (pH-7.4)  and 1 mM 
NaDPH at 37°C. The secondary reactions were terminated after incubation for 10 minutes by 
the addition 2 ml of ice-cold methanol containing 11α – hydroxyl progesterone as an internal 
standard. Samples were then vortexed, centrifuged and the formation testosterone metabolite, 
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6β- hydroxy testosterone was determined as previously described. A preincubation for 30 
minutes without NADPH (denoted as 0 minutes) was also performed which was used as 
control. At each concentration, the percentage of remaining CYP3A4 activity versus pre-
incubation time was plotted and the observed inactivation rate constant (Kobs) was estimated 
using the following equation, 
%	ܥܻܲ3ܣ4	ܽܿݐ݅ݒ݅ݐݕ	ݎ݁݉ܽ݅݊݅݊݃ ൌ 100	 ൈ ݁ି௄೚್ೞ௧ 
The KI and kinact for the time dependent inactivation of CYP3A4 were determined 
using the observed inactivation rate (Kobs) at each BEZ235 concentration, by nonlinear 
regression fitting equation 1 using WinNonlin. 
 
ܭ௢௕௦ ൌ ݇௜௡௔௖௧	 ൈ ሾܫሿܭூ ൅ ሾܫሿ  
 where KI, kinact and [I] are the BEZ235 concentration required for half-maximal 
inactivation, maximum rate of inactivation, and concentration of BEZ235, respectively. 
BEZ235 inhibition of everolimus metabolism was tested in HLMs using an IC50 shift method, 
where everolimus (5 µM) was incubated with different concentrations of BEZ235 (0.5 – 25 
µM) for 15 minutes in the presence of NADPH and remaining everolimus was quantified. 
Further, mechanism of inhibition was investigated through heme destruction studies at 
BEZ235 (10 and 20 µM). Formation of metabolic intermediate complex in HLMs was studied 
using spectral difference scanning spectroscopy between 400 nm – 500 nm at different 
concentrations of BEZ235 (0.1 µM – 25 µM).  
94 
 
4.4.3 Mechanism of CYP3A4 Inhibition by BEZ235 
4.4.3.1 Heme Destruction Studies 
Heme destruction studies were performed at 10 and 20 µM concentrations of 
BEZ235. CYP3A4 inactivation was initiated as mentioned above and after 30 min incubation 
at 37°C, the loss of the native heme was quantified using as HPLC method as described by 
Amunugama et.al (Amunugama, Zhang, & Hollenberg, 2012). The chromatographic system 
consisted of Waters 1525 pump connected to Waters 717 plus autosampler and Waters 2487 
dual λ UV-vis detector. Chromatographic separations were performed on a Waters Sunfire™ 
C4 column (4.6 mm × 250 mm). A gradient program consisted of 0.1% TFA in water (pump 
A) and 0.05% TFA in acetonitrile (pump B) changing from 70:30 (A:B) to 20:80 (A:B) over 
30 min using a linear gradient at a flow rate of 1 ml/min, and the column eluants were 
monitored at 400 nm for heme. 
4.4.3.2 Partition Ratio 
The partition ratio for the inactivation of CYP3A4 by BEZ235 was determined by 
incubating increasing concentrations of BEZ235 (0.5 – 25 µM) in rCYP3A4 and allowing the 
inactivation to proceed to completion. After 45 mins, the CYP3A4 activity remaining was 
determined using the formation of 6β- hydroxy testosterone assay as described earlier. The 
percent CYP3A4 activity remaining was plotted against the molar ratio of BEZ235 to 
rCYP3A4 to determine the turnover number.  
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4.4.3.3 Spectral Difference Scanning 
Formation of metabolic intermediate complex (MIC) was monitored by incubating 
rCYP3A4 along with 25 µM BEZ235. MIC formation was measured at intervals of 5 mins for 
45 mins using a UV/Vis spectrophotometer monitored between 400 – 500 nm to monitor the 
formation of an absorbance maximum at ~455 nm. The reference cuvette contained the 
incubation mixture without NADPH.  
4.4.4 CYP Induction Studies in Human Hepatocytes 
Primary human hepatocytes were plated in collagen-coated plates and maintained in 
Williams E medium as described previously(Hariparsad et al., 2004; Nallani et al., 2001; 
Nallani et al., 2003). Drug treatment was initiated within 48 hours after plating of 
hepatocytes.  Hepatocytes were treated with BEZ235 (0.01, 0.1, 1 and 10µM) or rifampicin 
(10 μM), for 72 hours and drug-containing medium was replaced every 24 hours for the 72-
hour period. After incubation, cells were exposed to 250 μM testosterone containing medium 
for 30 minutes and the formation of 6β-hydroxytestosterone by intact cells was used as 
marker for CYP3A4 activity. In another set of cells, total RNA was isolated and CYP3A4-
specific messenger RNA (mRNA) was quantified using real-time quantitative PCR analysis 
(Hariparsad et al., 2004; Nallani et al., 2001; Nallani et al., 2003). Emax, the maximum 
observed induction in hepatocytes and EC50, the concentration for half-maximal induction 
were estimated by fitting the induction data to a simple Emax model. (Sigmaplot 13.0, Systat 
Software, San Jose, CA)   
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4.4.5 Cell Based Pregnane-X Receptor (PXR) Activation Assay 
Transient transfection of human PXR was performed in human hepatocellular 
carcinoma cell line (HepG2) as described previously (Sane, Buckley, Buckley, Nallani, & 
Desai, 2008). HepG2 cells were seeded at 2 x 105 cells/well density in a 24-well plate in 
antibiotic-free Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% 
delipidated fetal calf serum. After 24-hour of plating, transient transfections were performed 
using Lipofectamine and Plus reagent (Invitrogen) (Hariparsad et al., 2004). Transfection 
mixes contained 75 ng of nuclear receptor expression vector, 75 ng of coactivators, 300 ng of 
luciferase reporter gene along with the promoter sequences of interest downstream of a 
luciferase reporter, and 300 ng of pCH110 (an expression vector containing β-galactosidase 
cDNA under T7 promoter) (Sane et al., 2008). After overnight transfection, fresh media 
containing BEZ235 (5, 10 and 25 μM) or positive control, rifampin (10 and 25 µM) or 
control, DMSO-containing media was replaced and incubated for a 48 hr period. Later, the 
cell layers were washed with ice-cold PBS (pH 7.4), scraped and treated with 200 μL of 
reporter lysis buffer (Promega). A 10 µl aliquot of the lysate was used for luciferase assay, 
which was performed using Luciferase Assay System (Promega). Further, a 50 μL of cell 
lysate was used to determine the β-galactosidase, which was used as an endogenous control 
for luciferase activity. In each treatment, luciferase activity normalized to the β-galactosidase 
activity was expressed as fold-activation with respect to the solvent treated controls.  
4.5 Assessment of Modulation of P-gp by BEZ235 (Caco-2 Uptake Studies) 
Caco-2 cells obtained from American Type Culture Collection (Manassas, VA) 
were cultured in Eagle's Minimum Essential Medium (MEM) supplemented with 10% fetal 
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bovine serum (FBS) in a humidified incubator with 5% CO2 at 37°C. Cells were plated on 75 
cm2 flask at a density of 1 X 106 cells/flask and were then harvested at 80% confluence with 
trypsin- EDTA. For uptake studies, Caco-2 cells were seeded onto 12-well plate at a density 
of 50,000 cells/well for 48 hrs. Initially, time dependent everolimus uptake was studied at 10 
µM everolimus concentration for different incubation times 5, 15, 30 and 45 minutes. 
Substrate uptake was stopped and rinsed three times with ice-cold PBS buffer. Cells were 
lysed by addition of 200 µL of lysis buffer. Cell lysate was centrifuged and analyzed for 
everolimus concentration using a LC-MS/MS method as mentioned previously. The protein 
content was determined with a BCA assay kit (Thermo Fisher Scientific) following the 
manufacturer's instructions. Everolimus uptake was linear in 5 – 30 min, and for further 
experiments incubation was proceeded for 15 min. Next, concentration dependent everolimus 
uptake was studied at 0.1, 1 and 10 µM concentrations of everolimus alone, also along with 
BEZ235 (0.5, 2, 10 and 25 µM) and prototypical P-gp inhibitor, elacridar (1 and 5 µM, IC50 
– 0.3µM). Everolimus uptake was stopped, cells lysed as indicated earlier, and everolimus 
concentration quantified using a LC-MS/MS method. Uptake was normalized with protein 
content as determined using BCA assay kit.  
4.6 Results 
4.6.1 Competitive Inhibition of CYP3A4 
In competitive studies using testosterone (125 μM) as a substrate along with 
BEZ235 (0.01 - 25 µM). The addition of BEZ235 resulted in no significant competitive 
inhibition (Figure 20). Even at the highest concentration of BEZ235 tested (25 µM, solubility 
limitations), the inhibition was only 93% suggesting BEZ235 is a weak inhibitor of CYP3A4. 
98 
 
However, positive control ketoconazole resulted in a significant reduction in the formation of 
6β-OH-testosterone, with an IC50 of 0.07 µM, which was close to the reported value (Patki, 
Von Moltke, & Greenblatt, 2003) (Figure 20). 
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Figure 20: Competitive inhibition study of BEZ235.  Effect of varying concentrations of 
BEZ235 (0 – 25 μM) on the metabolism of testosterone (125 μM), a prototypical 
CYP3A4 probe substrate, was evaluated in pooled human liver microsomes (HLM).  
Ketoconazole was used as a positive control. Percentage CYP3A4 activity remaining was 
plotted against the inhibitor concentration. 
4.6.2 Time Dependent Inhibition of CYP3A4 
The time- and concentration- dependent CYP3A4 inhibition potential of BEZ235 
was investigated using HLM. Initially, we investigated the effect of pre-incubation time on 
the magnitude of inhibition by measuring the rate of formation of 6β-hydroxy testosterone. 
Second, we investigated the involvement of mechanism-based inactivation by conducting 
preincubations with or without NADPH. As shown in Figure 21, BEZ235 at 10 μM inhibited 
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CYP3A4 in a NADPH dependent manner, and there was no significant decline in CYP3A4 
activity in the absence of NADPH in HLM incubations.  
 
Figure 21: NADPH-dependent inactivation of CYP3A4 by BEZ235 in HLM. Effect of 
BEZ235 (10 μM) on the formation of 6β hydroxy testosterone metabolite with or without 
NADPH was evaluated in pooled human liver microsomes (HLM).   
In the next set of experiments with different concentrations of BEZ235, there was a 
concentration- and time-dependent inhibition of CYP3A4 activity in the presence of BEZ235. 
The rate of inactivation, Kobs, was calculated as the slope of logarithm plot of residual 
enzymatic activity against the pre-incubation time at different BEZ235 concentrations (Figure 
22). The plot of Kobs vs BEZ235 concentration was analyzed for the determination of kinact and 
KI (Figure 23). Maximal inactivation rate constant, kinact was 0.0175 ± 0.0024 min-1and KI of 
inhibition was 5.213 ± 2.092 μM. The inactivation half-life, t1/2inact, was calculated to be 36.55 
min. The inactivation efficiency Einact, calculated as a ratio of kinact/KI, was 0.00336 min-1/ μM 
Table 16.  
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Figure 22: Time- and concentration-dependent inactivation of CYP3A4 by BEZ235 in 
HLM. Plot of pre-incubation time and natural logarithm of percentage CYP3A4 activity 
remaining after time dependent inhibition at different concentrations of BEZ235.  
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Figure 23: Determination of kinetics of time dependent inhibition. Plot of Kobs against 
BEZ235 concentrations. Rates for time-dependent inactivation at different BEZ235 
concentrations were fit to Michaelis-Menten equation to obtain KI and kinact of time 
dependent inhibition of CYP3A4 by BEZ235. 
 
 
Table 16: Kinetic parameters of time-dependent inhibition of CYP3A4 by BEZ235 
Parameter Value 
kinact (min-1) 0.0175 ± 0.0024 
KI (μM) 5.213 ± 2.092 
R square 0.7174 
Estimation of inactivation efficiency, Einact (min‐1/ μM) 0.00336 
Inactivation half-life, t1/2inact (min) 39.55 
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4.6.3 Mechanism of CYP3A4 Inhibition 
4.6.3.1 Heme Destruction Studies 
The loss of native heme was monitored using a HPLC method. As shown in Figure 
24, native heme eluted at approximately 11 min. Upon incubation with BEZ235 in the 
presence of NADPH at 37Ԩ for 30 min, there was significant decrease in area of heme peak 
(Table 17). A significant loss (14-20%) in native heme in the inactivated sample compared 
with the control sample was observed. However, there were no additional peaks in the HPLC 
chromatogram indicating that BEZ235 inactivation may lead to heme fragmentation or to 
unstable heme adducts that were not detectable. 
Table 17: Heme destruction studies: Results of change in peak area of native heme after 
inactivation with 10 and 20 µM concentration of BEZ235 
 
Control  
(30 min incubation without 
NADPH) 
Test  
(30 min incubation 
with NADPH) 
% reduction 
compared to 
control 
BEZ235 10 µM 
86466 61472 
19.17 
104264 84163 
97194 87090 
Average 95974.67 77575.00 
% CV 9.34 18.08 
BEZ235 20 µM 
87980 76662 
13.84 
92748 71890 
81154 77075 
Average 87294.00 75209.00 
% CV 6.68 3.83 
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Figure 24: HPLC chromatogram of native heme. Prosthetic heme was analyzed using a 
HPLC method monitored at 400 nm. HLM incubated with various concentrations of 
BEZ235 were analyzed for the loss of native heme. 
4.6.3.2 Partition Ratio 
The partition ratio, which is the number of BEZ235 molecules metabolized per 
molecule of enzyme inactivated, was measured using rCYP3A4 as described in methods. As 
previously described inactivation was performed with various concentration of BEZ235 to 
completion and 6β-hydroxytestosterone was used to measure residual CYP3A4 activity.   
Figure 25 shows the plot of residual CYP3A4 activity versus molar ratios of BEZ235 to 
CYP3A4. Partition ratio is calculated by extrapolating the intercept of the linear regression 
line of the higher ratios (shown in blue) and the linear regression of the lower ratios (shown in 
red) resulting in a turnover number of 19. Subtracting one from this value yielded a partition 
ratio of 18. 
H
em
e 
- 1
1.
18
1
AU
-0.004
-0.002
0.000
0.002
0.004
0.006
0.008
0.010
0.012
0.014
0.016
0.018
0.020
0.022
Minutes
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00 16.00 17.00 18.00 19.00 20.00 21.00 22.00 23.00 24.00 25.00
104 
 
 
Figure 25: Partition ratio of inactivation of CYP3A4 by BEZ235. HLM were incubated 
for various concentrations of BEZ235 for 60 min with NADPH until the inactivation is 
complete and the percentage CYP3A4 activity remaining was determined. Partition 
ratio was determined from the intersection of regression line for the lower (blue) and 
higher (red) BEZ235 concentrations.  
4.6.3.3 Spectral Difference Scanning 
Formation of metabolite-intermediate complex (MIC) resulting in a characteristic 
peak in the Soret region (448–458 nm) wamonitored. Spectral differences monitored 400 to 
500 nm during incubation of HLM with BEZ235 produced a distinct change in the absorbance 
in the range 448 to 458 nm, indicating the formation of MIC (Figure 26).  
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Figure 26: Spectral difference scanning of HLM after inactivation with BEZ235. HLM 
incubated with various concentrations of BEZ235 in the presence of NADPH were 
monitored between 400 to 500 nm. Spectral difference scans were measured at different 
incubation times to detect the formation of metabolic intermediate complex. 
4.6.4 CYP Induction Studies in Human Hepatocytes 
In primary human hepatocytes, BEZ235 caused a concentration-dependent decrease 
in CYP3A4 activity, in contrast to rifampicin, which significantly increased CYP3A4 activity 
(Figure 27). There was 1.5-3.5 fold increase in CYP3A4 activity upon 72 hours treatment of 
hepatocytes with prototypical inducer rifampin. However, BEZ235 in both liver hepatocytes 
resulted in decreased CYP3A4 activity, and at concentrations above 1 µM resulted in 
complete loss of CYP3A4 activity. In contrast, as shown in Figure 28, BEZ235 treatment 
resulted in a concentration-dependent increase in CYP3A4-specific mRNA levels. There was 
a 1.7 – 2.4 fold increase in CYP3A4 mRNA levels at the highest concentration tested of 
BEZ235 - 10 µM, which was 50-60% of the fold change after 10µM of rifampin treatment.  
Emax, the maximal activation observed in hepatocytes incubation was 2.78 and EC50, the 
0 min
45 min
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concentration for half-maximal response was calculated to be 1.955 µM, as shown in Figure 
29. 
 
Figure 27: Fold change in CYP3A4-activity. Primary human hepatocytes, isolated from 
lobes of donor livers as surgical surplus, were incubated with BEZ235 (0.01 -10 µM) or 
Rifampin (10 µM) for 72 hours. The testosterone 6β hydroxylase activity was used as a 
marker for the CYP3A4 activity. Plotted here is the fold change in treatment when 
compared with vehicle treated control in two batches of hepatocytes.  
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Figure 28: Fold change in CYP3A4-specific mRNA levels. Primary human hepatocytes, 
isolated from lobes of donor livers as surgical surplus, were incubated with BEZ235 
(0.01 -10 µM) or Rifampin (10 µM) for 72 hours. The CYP3A4 mRNA was quantified 
using RT-PCR analysis. Plotted here is the fold change in treatment when compared 
with vehicle treated control in two batches of hepatocytes. 
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Figure 29: CYP3A4 induction Emax and EC50 of BEZ235. CYP3A4 mRNA levels were fit 
to Emax model to estimate the maximal induction Emax and the concentration for half-
maximal response, EC50 of the induction.  
 
4.6.5 Cell Based Pregnane-X Receptor (PXR) Activation Assay 
Human PXR activation by BEZ235 was examined by transient transfection of a 
hPXR -responsive regions of the CYP3A gene in HepG2 cells. Rifampin as positive control 
increased PXR activity by 7.6 and 8.2 fold at 10 and 25 µM, respectively. BEZ235 at 
concentrations of 5, 10, and 25 μM increased hPXR activation by 4.9, 6.1 and 6.1-fold, 
respectively (Figure 30). Similarly, everolimus also increased hPXR activation, however, its 
effect was less pronounced relative to BEZ235. Treatment with everolimus resulted in a 1.8 – 
3.4 fold increase in luciferase activity at concentrations ranging from 5- 25 µM. Further 
combination of BEZ235 and everolimus at an equimolar concentration of 12.5 µM resulted in 
a 6.6 fold increase in hPXR activation. 
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Figure 30: Fold change in luciferase activity of hPXR in HepG2 cells. The human 
hepatocellular carcinoma cell line (HepG2) was transiently transfected with CYP3A4 
promoter reporter plasmid and nuclear receptor expression plasmids using 
Lipofectamine® and Plus®  reagents.  Cells were treated with BEZ235 and/or 
everolimus at varying concentrations along with CYP3A4 inducer rifampin (10 and 25 
μM) for 72 hrs. Cell lysate was used to determine luciferase activity for quantification of 
PXR activity. Plotted here is the fold change in treatment when compared with vehicle 
treated control. 
4.6.6 Caco-2 Uptake Studies 
The contribution of efflux transporter, P-gp in the interaction of everolimus and 
BEZ235, was investigated employing the colon carcinoma caco-2 cell lines. Everolimus 
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uptake at different concentrations (0.1, 1 and 10 µM) were measured alone and in the 
presence of BEZ235 (0.5, 2, 10 and 25 µM) and prototypical P-gp inhibitor, elacridar (1 and 5 
µM, IC50 – 0.3µM). As shown in Figure 31, BEZ235 did not affect the everolimus uptake 
even at concentrations up to 25 µM. 
 
Figure 31: Everolimus uptake in Caco-2 cells in the presence of BEZ235. Everolimus 
uptake at 0.1, 1 and 10 µM was quantified with various concentrations of BEZ235 (0.5 – 
25 µM). Plotted here is the change percentage change in treatment groups when 
compared with vehicle control. 
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5 Aim 3: To Establish a Mechanistic Physiology Based Pharmacokinetic 
Model (PBPK) to Predict and Study the Pharmacokinetic Interaction 
Between BEZ235 and Everolimus 
 In the UC Phase I clinical trial combining BEZ235 with everolimus, there was a 
significant change in steady state pharmacokinetics of everolimus. Quantification of the 
extent and mechanism of complex drug interactions in early-phase trials of drug combinations 
are challenging due to the limited sample size and insufficient statistical power in these trials. 
Mechanistic PBPK models have been proposed for prospective prediction of clinical outcome 
of interaction of combination therapies. Early identification of complex drug–drug 
interactions and quantitative prediction of their impact are of great importance to the rational 
development and optimal use of anticancer drugs such as BEZ235, a PI3K/mTOR intended to 
be combined with other cytotoxic and targeted agents for a number of cancers. Herein, we 
utilized a mechanistic modeling using physiologically based pharmacokinetic model to 
quantitatively predict the extent and mechanism of the interaction. This study provides further 
quantitative insights into the interactions of BEZ235 with metabolizing enzyme CYP3A4 and 
its consequence on everolimus pharmacokinetics. This information is critical for aiding in 
decision-making for further clinical trials combining BEZ235 and everolimus, and also in 
guiding dose optimization based on the complex drug interactions. 
5.1 Mechanistic Static Model 
 A mechanistic physiology based pharmacokinetic model (PBPK) to predict and 
study the pharmacokinetic interaction between BEZ235 and everolimus was developed. The 
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change in everolimus exposure (AUC) in the presence of various doses of BEZ235 was 
calculated using a mechanistic static model based on the net effect of time dependent 
inactivation and induction of CYP3A4 in both the intestine and liver as described as in 
Equation 1.(Fahmi et al., 2008)  
ܣܷܥ௣௢,௜
ܣܷܥ௣௢ ൌ 	
1
ሾܣ ∗ ܤሿ ∗ ݂݉஼௒௉ଷ஺ସ ൅ ሺ1 െ	݂݉஼௒௉ଷ஺ସሻ ∗ 	
1
ሾܥ ൅ ܦሿ ∗ ሺ1 െ	 ீܨ ሻ ൅ 	ீܨ  
Equation 1 
 
Where,  
ܣ ൌ 	 ݇ௗ௘௚
݇ௗ௘௚ ൅	ܭ௜௡௔௖௧ 	∗ 	 ሾܫሿுܭூ ൅	ሾܫሿு
 
ܤ ൌ 1 ൅	݀	 ∗ 	ܧ௠௔௫ 	∗ 	 ሾܫሿுܧܥହ଴ ൅	ሾܫሿு  
ܥ ൌ 	 ݇ௗ௘௚
݇ௗ௘௚ ൅	ܭ௜௡௔௖௧ 	∗ 	 ሾܫሿீܭூ ൅	ሾܫሿீ
 
ܦ ൌ 1 ൅	݀	 ∗ 	ܧ௠௔௫ 	∗ 	 ሾܫሿீܧܥହ଴ ൅	ሾܫሿீ  
Input parameters for this model included a number of in vitro and in vivo 
pharmacokinetic parameters of BEZ235 and everolimus.  
The KI and kinact represent BEZ235 time dependent inhibition kinetics, and EC50 
and Emax represent CYP3A4 induction potential of BEZ235. Everolimus fraction eliminated 
through metabolism, fm was 1 and fraction metabolized by CYP3A4, fm, CYP3A4 was 0.93 
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(Picard et al., 2011). FG, fraction of everolimus escaping gut was 0.3(Chow & Pang, 2013). 
The degradation rate of CYP3A4 kdeg in liver and intestine was 0.0193 and 0.0288 hr-1 
respectively (Galetin et al., 2006). The abundance of a CYP3A4 enzyme in an individual can 
be expressed as a dynamic relation between zero order synthesis rate and a first order 
degradation.  
݀ܧ௧
݀ݐ ൌ ܴ௦௬௡ െ ݇ௗ௘௚ ൈ	ܧ௧ 
Where Et, is the enzyme level at any time t, Rsyn and kdeg are the rate of enzyme 
synthesis and degradation rate, respectively. At the basal level and when the rate of synthesis 
and degradation is at equilibrium,  
ܴ௦௬௡ ൌ 	ܧ௕௔௦௘௟௜௡௘ ൈ	݇ௗ௘௚ 
Where Rsyn and kdeg are the basal rate of enzyme synthesis and basal degradation 
rate, and Ebaseline is the basal level of enzyme. However in the presence of “perpetrator” which 
can alter either synthesis via induction or degradation via mechanism-based inactivation. The 
dynamic equilibrium of CYP3A4 can be expressed as,  
݀ܧ௧
݀ݐ ൌ ቈܧ௕௔௦௘௟௜௡௘ ൈ	݇ௗ௘௚ ൈ ቆ1 ൅
ܧ௠௔௫ ൈ ሾܫሿ௧
ܧܥହ଴ ൅ ሾܫሿ௧ቇ቉ െ ቈ	݇ௗ௘௚ ൈ ቆ
݇௜௡௔௖௧ ൈ ሾܫሿ௧
ܭூ ൅ ሾܫሿ௧ ቇ ൈ ܧ௧቉ 
Where [I] represent the BEZ235 concentration at the enzyme site.  
5.1.1 Impact of [I]G and [I]H Concentrations 
BEZ235 hepatic concentration, [I]H, can be represented in four different 
approaches, in vivo the total plasma Cmax, unbound free Cmax, total hepatic inlet Cmax 
estimated after oral administration, and unbound free hepatic inlet Cmax, BEZ235 plasma Cmax  
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was obtained from the Phase I study conducted at University of Cincinnati. BEZ235 hepatic 
inlet concentrations were calculated using following relation. 
ሾܫሿு ൌ 	ܥ௠௔௫ ൅	ܦ݋ݏ݁. ݇௔. ܨ௔ܳ௛  
Equation 2 
Here, ka is the first order absorption rate of BEZ235 estimated from the Phase I 
study and Fa , the fraction of BEZ235 dose that is absorbed into the gut wall, was assumed to 
be 0.25, and Qh, hepatic blood flow was 90 L/h. BEZ235 intestine concentration, [I]G, was 
estimated using the following relation, 
ሾܫሿீ ൌ 	ܨ௔ ൈ	݇௔	 ൈ ܦ݋ݏ݁	ܳ௘௡௧  
Equation 3 
Here, enterocytic blood flow (Qent) was assumed to be 18 L/h. For the above 
equation it is assumed that the BEZ235 follows a first order absorption and dissolution is not 
a rate limiting step, and is also not subject to major gut metabolism.  The FDA recommended 
approach in calculating the impact of  interaction is by using total Cmax for [I]G and dose over 
250 mL was also evaluated. 
5.2 Mechanistic Dynamic Model 
Physiologically based pharmacokinetic modeling and simulation were performed 
using population-based simulator SimCYP (version 14.0) (Jamei et al., 2009). The SimCYP is 
a commercially available platform for performing Model Based Drug Development (MBDD). 
SimCYP implements PBPK models that describe drug disposition using physiological 
compartmental system anatomical body tissues and organs.   
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5.2.1 Model Building Process 
5.2.1.1 Physiochemical Properties 
Molecular weight, logarithm of the octanol-buffer partition coefficient (log P), 
dissociation constant (pKa), polar surface area (PSA) and number of hydrogen bond donors 
(HBD) of BEZ235 (compound ID: CHEMBL1879463) were obtained from ChEMBL 
database (Gaulton et al., 2012). Blood to plasma ratio was set at SimCYP default of 0.55 and 
hematocrit was 45%. The fraction unbound in plasma (fu) was estimated using 
ultracentrifugation using Centrifree® tubes with a molecular weight cutoff of 30K (EMD 
millipore, Darmstadt, Germany). Fraction unbound in plasma of BEZ235 was 0.01%.  
Similarly everolimus physiochemical properties were obtained from ChEMBL 
database. Blood to plasma ratio of everolimus is concentration dependent and ranges from 
17% to 73% (between 5 to 5,000 ng/mL). Plasma protein binding in humans is 74% and free 
fraction unbound in plasma, Fu of everolimus was 0.25(Laplanche et al., 2007).  
5.2.1.2 Absorption 
Absorption of BEZ235 was described using a first order absorption model with lag 
time. The parameters describing the absorption kinetics were estimated from the observed 
clinical data using parameter estimation model implemented within SimCYP and also using 
population pharmacokinetic model of BEZ235 developed using NONMEM. Final parameters 
are listed in Table 18. The “Qgut” model in SimCYP was implemented; it represents a hybrid 
parameter, 
ܳ௚௨௧ ൌ 	 ܳ௏௜௟௟௜ ∗ ܥܮ௣௘௥௠ܳ௏௜௟௟௜		 ൅ ܥܮ௣௘௥௠ 
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Equation 4 
where CLperm represents the permeability clearance calculated from the effective 
permeability, Peff, predicted based on HBD and PSA as shown in Equation 5(Winiwarter et 
al., 1998).  
௘ܲ௙௙ ൌ 2.546 െ 0.011 ൈ ܲܵܣ െ 0.278 ൈ ܪܤܦ 
Equation 5 
The fraction of BEZ235 escaping gut, Fgut, is estimated from Qgut as,  
ீܨ ௨௧ ൌ ܳ௚௨௧ܳ௚௨௧ ൅	 ௨݂ ∗ ܥܮ௜௡௧  
Equation 6 
An advanced dissolution, absorption and metabolism model (ADAM) was used for 
the absorption profile of immediate release formulation of everolimus. The ADAM model 
incorporates nine compartments of gut with differential distribution of enzyme and 
transporters facilitating a realistic simulation of gut absorption, transport, metabolism and 
interactions. The effective permeability (Peff) was predicted from Caco-2 permeability data of 
everolimus using Equation 7 (Crowe et al., 1999; Crowe & Lemaire, 1998; Sun et al., 2002). 
௘ܲ௙௙ ൌ 0.4926 ൈ log ௔ܲ௣௣,			஼௔௖௢ିଶ െ 0.1454 
Equation 7 
 
5.2.1.3 Distribution 
The minimal PBPK model was used for describing BEZ235 distribution. It is one 
of the simplest models consisting only of four compartments, the systemic, portal vein and 
liver and a single adjusting compartment (SAC). The SAC is a non-physiological 
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compartment, which represents a lump of all tissues excluding the liver and portal vein. 
BEZ235 distribution was described by a minimal PBPK model with SAC and the volume of 
distribution (Vss) was estimated using “Method 1” based on Poulin and Theil (Poulin & Theil, 
2002). Similarly, everolimus distribution was described using a minimal PBPK model with 
SAC and Vss was estimated using “Method 1”. Volume of SAC estimated by fitting clinically 
observed data using the parameter estimation module provided within SimCYP. 
5.2.1.4 Elimination 
A minimal model of clearance using overall in vivo oral clearance (CLpo) was used 
in SimCYP for BEZ235 elimination. Since there is less evidence on the route of BEZ235 
elimination, CLpo represents a summation of elimination through all pathways including 
metabolic and non-metabolic clearance. Oral clearance of BEZ235 was estimated from 
population pharmacokinetic model of BEZ235 developed using NONMEM. Everolimus 
elimination was described by enzyme kinetics of CYP3A4 obtained from in vitro metabolism 
studies (Dannecker, Vickers, Ubeaud, & Hauck, 1998; Laplanche et al., 2007).  
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5.2.1.5 Interaction Module 
For studying drug-drug interaction potential of BEZ235, in vitro parameters of its time 
dependent inhibition and induction potential were included into the PBPK model.  The SimCYP 
induction and inhibition models uses a mechanistic model representing the expression of CYP 
enzyme pool, which is increased by induction and depleted by enzyme inhibition (irreversible 
time dependent inhibition here). BEZ235, kinetic parameters that characterize time dependent 
inhibition, kinact and KI are obtained from in vitro experiments. Similarly, BEZ235 induction 
potential, EC50 and Emax, were obtained from primary human hepatocytes as mentioned in section 
4.4.4.   
5.2.2 Model Qualification 
BEZ235 and everolimus PBPK models were qualified using internal and external 
clinical data. Everolimus PBPK model was qualified using reported pharmacokinetic parameters 
obtained when dosed alone and also along with CYP3A4 modulators such as ketoconazole, 
erythromycin, verapamil, and rifampin (Table 19) (Kovarik, Beyer, Bizot, Jiang, Allison, et al., 
2005; Kovarik, Beyer, et al., 2005a, 2005b; Kovarik et al., 2006; Kovarik et al., 2002)  
Table 19: Reported drug drug interactions of everolimus 
Type of perpetrator Test regimen 
Fold 
increase in 
everolimus 
AUC 
Reference 
CYP3A inhibitor Strong Ketoconazole 200mg 15 
(Kovarik, Beyer, et al., 
2005a) 
CYP3A inhibitor Moderate Erythromycin 500mg 4.4 
(Kovarik, Beyer, et al., 
2005b) 
CYP3A and P-gp 
inhibitor Moderate 
Verapamil 80 
mg 3.4 
(Kovarik, Beyer, Bizot, 
Jiang, Allison, et al., 2005)
CYP3A induction Strong Rifampin 600 mg 0.37 (Kovarik et al., 2002) 
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For BEZ235 PBPK model, plasma concentrations from the Phase I trial at three 
different BEZ235 doses were used.  
5.2.3 Trial Simulation 
All the simulations were performed using healthy volunteer population built into 
SimCYP®. For comparing the results from reported clinical trials, the number of subjects, age 
range and gender ratio, dose regimen was modified according to the trial design reported. In this 
current study, drug interaction between everolimus 2.5 mg orally given along with BEZ235 (200, 
400, and 800 mg) once daily was simulated. The number of trials was kept at 10 trials of 10 
subjects each to assess inter-study variability. 
5.3 Evaluation of Model Predictability  
The static and dynamic model predicted AUC ratios were compared with the observed 
interaction from the clinical trial at three different doses of BEZ235. Percentage prediction error 
(PPE) was calculated as shown in  
Equation 8. The bias and precision of the prediction were also assessed with root mean 
square error (RMSE), and average-fold error (AFE), shown in  
Equation 9 and Equation 10, respectively. 
ܲܲܧ	ሺ%ሻ ൌ 100. 1ܰ෍
ܲݎ݁݀݅ܿݐ݁݀ െ ܱܾݏ݁ݎݒ݁݀
ܱܾݏ݁ݎݒ݁݀  
Equation 8 
ܴܯܵܧ ൌ ඨ෍ሺܲݎ݁݀݅ܿݐ݁݀ െ ܱܾݏ݁ݎݒ݁݀ሻ
ଶ
ܰ  
Equation 9 
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ܣܨܧ ൌ 	10ଵே∑ቚ୪୭୥భబ௉௥௘ௗ௜௖௧௘ௗை௕௦௘௥௩௘ௗ ቚ 
Equation 10 
ܰ െ ݊ݑܾ݉݁ݎ	݋݂	݋ܾݏ݁ݎݒܽݐ݅݋݊ݏ 
5.4 Sensitivity Analysis 
PBPK model predictions are based on a number of system dependent physiological 
parameters and compound-specific parameters. Variability and uncertainty associated with these 
parameters can influence the model predictions. A sensitivity analysis was performed to evaluate 
the influence of these uncertainty and variability of input parameters on the sensitivity of model 
predictions.  
Influence of system dependent parameters such as, degradation rate of CYP3A4 
(Kdeg), variability in enzyme expression were tested. Intrinsic levels of CYP3A4 at steady state 
can be expressed as a ratio of the zero-order enzyme synthesis rate and the first-order enzyme 
degradation rate (Kdeg). This critical in vivo parameter has the most uncertainty, as it is not 
ethically possible to measure this directly in humans. There are a number of different values of 
Kdeg reported, 0.0077 h-1 (t1/2 – 90.3 h) (J. Yang et al., 2008), 0.025 h-1 (t1/2 – 27.8 h) (Quinney 
et al., 2010), 0.030 h-1 (t1/2 – 23.1 h)(Greenblatt et al., 2003). 
Variability in fm, fraction of everolimus metabolized,  which depends on relative 
variability in metabolic routes, is a common cause of inter-individual differences metabolism 
based drug interactions.  
The effect of BEZ235 inactivator concentration at the gut and liver can significantly 
affect the model predictions.  Further uncertainty in the kinetic parameters of time dependent 
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inhibition and induction, such as Ki, kinact and fraction unbound in plasma of BEZ235 (Fu) were 
tested.   
5.5 Results 
5.5.1 Mechanistic Static Model  
Using the net effect model, the extent of drug-drug interaction of everolimus along 
with BEZ235 is shown in the Figure 32. The predictions based on static model are in good 
agreement with the observed values. The AUC ratio prediction based on total BEZ235 plasma 
Cmax as inhibitor concentration at the hepatic site, [I]H , resulted in over prediction of interaction. 
Using more physiologically relevant [I]H such as free portal Cmax and unbound Cmax improved the 
predictions. Unbound Cmax model predictions were closer to the observed interaction; PPE and 
AFE were 58% and 1.58, respectively (Table 20). The predictions based on the FDA 
recommended approach of total plasma Cmax over predicted the interaction that ranged from six 
to twelve-fold increase in everolimus AUC. 
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Figure 32: Impact of [I]G and [I]H of BEZ235 on everolimus interaction. Plot of BEZ235 dose against the fold 
change in everolimus AUC calculated using various [I]G and [I]H concentrations of BEZ235. Red diamond 
represents total plasma Cmax, green diamond represents unbound portal Cmax, and blue diamond represents 
unbound plasma Cmax.  
5.5.2 Mechanistic Dynamic Model 
PBPK model predictions of BEZ235 plasma concentration after 200, 400 and 800 mg 
once daily are shown in Figure 33. At all the dose levels, the PBPK predictions were in good 
agreement with observed data Table 20. Similarly, PBPK model prediction of everolimus 
concentration-time profile when dosed alone was in good agreement at 5 and 10 mg once daily. 
Further, the model was also used to predict the interaction of everolimus with other CYP3A4 
modulators such as ketoconazole, erythromycin, verapamil and rifampin as shown in the Table 
21. In all the three interactions, the model predicted fold change in AUC, Cmax  were close to the 
observed interactions, and AFE of prediction was 1.65 for AUC ratio and 1.41 for Cmax ratio. 
Using the PBPK model for everolimus and BEZ235, the interaction was simulated at 
2.5 mg once daily for everolimus along with 200, 400 and 800 mg BEZ235. The model predicted 
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fold change in everolimus AUC, Cmax and clearance are shown in the Table 22. Fold change in 
AUC ranged from 1.64, 1.81, and 2.05 at 200, 400 and 800 mg respectively, which was close to 
the observed fold change in Phase I clinical study. The PPE was less than 5% and RMSE was 
0.08 showing good argument between observed and predicted interactions. The impact of 
BEZ235 on CYP3A4 activity in gut and intestine is shown in Figure 34, and there is a 5-fold 
(~20%) reduction in gut CYP3A4 whereas the liver CYP3A4 levels were decreased by only 
15%.  Further, the change in everolimus fraction metabolized at different segments of GIT is 
shown in Figure 34, and there is a significant reduction in the metabolism of everolimus, leading 
to an increase in Fg. 
5.5.3 Sensitivity Analysis 
A sensitivity analysis on influence of degradation rate of CYP3A4, Kdeg on the 
prediction of fold change in everolimus AUC in the presence of BEZ235 is shown in Figure 35. 
kdeg had a significant effect on the interaction, fold change in everolimus AUC ranged from 3 at 
Kdeg of 0.03 h-1 to almost 7 fold at 0.005 h-1.  Further, these results were not affected by BEZ235 
concentration. Similarly, influence of plasma protein binding on DDI prediction is shown in 
Figure 36, fold change in everolimus AUC decreased from 9 folds to 3.5 folds when unbound 
fraction of BEZ235 changed from 0.1 to 0.01. These results suggest that the interaction is more 
sensitive and to be impacted to a greater extent by these parameters.  
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Figure 33: BEZ235 PBPK model qualification – Predictions and observed plasma 
concentration of BEZ235 at different dose levels; (a) 200 mg/ day; (b) 400 mg/ day; (c) 800 
mg/ day. Solid blue is the SIMCYP predicted mean concentrations and dashed red line are 
the 5th and 95th percentile of the predictions. Solid purple line represents the mean 
observed concentrations with standard deviation at 200, 400 and 800 mg/day of BEZ235.  
 
Table 22: Summary of DDI predictions using mechanistic PBPK model  
BEZ235 Dose (mg) Observed AUC ratio Mechanistic dynamic model using SimCYP® 
200 1.57 1.64 
400 1.71 1.81 
800 2.13 2.05 
Percentage prediction error, PPE 4.69 
Root mean square error, RMSE 0.08 
Average-fold error, AFE 1.05 
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Figure 34: Effect of BEZ235 treatment on the intrinsic metabolism of everolimus. A) 
Prediction of fraction of everolimus dose metabolized in different parts of intestine using 
ADAM model, which includes segregated blood flow, and regional abundance of CYP3A4 
in different sections of the GI. Blue bars represent the fraction of everolimus dose 
metabolized without BEZ235 interaction, red bars represent the fraction of everolimus 
dose metabolized with BEZ235  B) Percentage of CYP3A4 activity remaining at different 
time points in gut and liver after treatment in the presence of BEZ235 (green) and without 
BEZ235 (red). 
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Figure 35: Sensitivity analysis: Effect of degradation rate of CYP3A4, kdeg and BEZ235 [I] 
concentrations. Fold change in everolimus AUC as a function of degradation rate of 
CYP3A4, kdeg and BEZ235 [I] concentrations is plotted.  
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Figure 36: Sensitivity analysis: Effect of BEZ235 [I] concentrations and plasma protein 
binding of BEZ235. Fold change in everolimus AUC as a function of [I] inhibitory BEZ235 
concentrations and plasma protein binding of BEZ235 is plotted.  
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6 Discussion 
The PI3K/Akt/mTOR pathway is an important signal transduction pathway in many 
essential cellular functions, which has been found to be aberrantly activated in a number of 
cancers. Accumulating evidence from genetic studies reveal that the PI3K/Akt/mTOR pathway 
harbors somatic or germline mutations in a wide range of human cancers, making this a 
favorable target for therapeutic intervention in cancer. Substantial drug discovery efforts have 
been devoted, over the last few years, to identifying and developing inhibitors targeting this 
signaling axis. A number of MTAs are in various stages of preclinical and clinical development 
targeting different nodes of PI3K/Akt/mTOR pathway. Despite a substantial preclinical evidence 
of tumor suppressing activity of these agents, the clinical outcome so far has been sobering and a 
number of roadblocks have been identified as key factors in translating the preclinical success. 
Firstly, it is evident that inhibition of this signaling axis at one node is not adequate, frequently 
resulting in activation through negative feedback mechanisms suggesting that a combination of 
multiple inhibitors is required to produce a more sustained inhibition of the target.  Secondly, 
identification of dosing range of these MTAs that effectively inhibits the target while being safe 
and tolerable in patients is challenging.  
BEZ235 is a novel imidazoquinoline derivative that inhibits PI3K and mTOR kinase 
activity. It has favorable preclinical pharmacokinetics, and exhibited superior anti- tumor activity 
in a number of mouse xenograft models, including models of glioblastoma multiforme, breast 
cancer and prostate cancer (Maira et al., 2008). Everolimus is a potent allosteric inhibitor of 
mTORC1 and is currently approved for the treatment of advanced renal cell carcinoma, 
pancreatic neuroendocrine tumor, SEGA and breast cancer, with its role in other cancers being 
evaluated as a single agent or in combination with other MTAs (Baselga, Campone, et al., 2012; 
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Bracarda et al., 2012; Krueger et al., 2010; US-FDA - clinical pharmacology and 
biopharmaceutics review; Yao et al., 2011). The combination of BEZ235 and everolimus has 
been found to have synergistic anti-tumor activity in both carcinogen-induced and xenograft 
mouse model of cancers including hepatocellular carcinoma and GBM (Nyfeler et al., 2012; 
Thomas et al., 2012). In a mouse model of HCC, the combination resulted in a significant 
number of genes reverting to baseline expression levels of normal liver and also resulted in the 
induction of autophagy. These results led to an investigator initiated a Phase 1b-2 clinical trial to 
determine the safety, pharmacokinetics and pharmacodynamics of the combination of BEZ235 
with everolimus in subjects with advanced solid tumors. Here we describe 1) the first report of 
clinical pharmacokinetics of BEZ235 at doses ranging from 200 to 800 mg when given along 
with everolimus at 2.5 mg once daily, and investigation of plausible pharmacokinetic interaction 
between BEZ235 and everolimus, 2) Correlative studies to delineate the mechanism of this 
interaction, 3) mechanistic modeling to understand the impact of physiological and drug specific 
parameters on the drug interaction. 
An open-label, single arm, dose escalation Phase 1b study of combination of BEZ235 
with everolimus in subjects with advanced solid malignancies was conducted at the UC cancer 
institute. The primary objective was to determine the safety and tolerability of the combination. 
The secondary objectives were to characterize the pharmacokinetics of BEZ235 and everolimus 
in combination. The starting dose was 200 mg for BEZ235 along with 2.5 mg of everolimus 
given once daily. Out of 34 patients with advanced solid tumors screened for the study, 19 were 
enrolled in the clinical trial. Patients with pathologically confirmed advanced solid tumors who 
had exhausted all therapies were eligible for enrollment in the trial. Key inclusion criteria 
included ECOG performance status of ≤ 2 and at least one measurable lesion.  We excluded 
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patients with previous treatment with PI3K inhibitors and also concomitant treatment with other 
drugs that are known to be strong inhibitors or inducers of the CYP3A4. Initially the study was 
planned to include five cohorts up to a highest dose of 1000 mg of BEZ235 along with 5 mg of 
everolimus. However, due to toxicity and lack of efficacy, the trial was terminated at cohort 3. 
Four patients developed dose limiting toxicities, which required withdrawal from the study. All 
19 patients reported at least one adverse event (all grades) and most common adverse events 
were fatigue, mucositis, diarrhea, nausea, and vomiting. In cohort 1, the combination treatment 
was tolerated well, all except one other patient completed the two full cycles. There were three 
serious adverse events, but only one with elevation in liver enzymes was deemed to be study 
drug related. In the dose cohort two, majority adverse events were related to laboratory 
abnormalities including elevated liver enzymes and anemia. In both these cohorts, patients 
progressed on disease requiring discontinuation from the study. In cohort three (BEZ235 at 800 
mg with 2.5 mg everolimus) one patient showed a transient clinical response at fifteen days; 
however, he developed grade 3 laboratory abnormalities requiring a delay in treatment. These 
adverse events were similar to other dual PI3K/mTOR inhibitors in clinical study including 
BGT226, XL765 and GDC-0980 (B. Markman et al., 2012; Shapiro et al., 2014; Wagner et al., 
2011). Mucositis and hyperglycemia are well-documented adverse effects of everolimus 
treatment. In this trial, despite the relative low dose level of everolimus (2.5 mg) compared to the 
standard therapy of 10 mg/day, the incidence of mucositis (grade 3–4) was observed in cohorts 2 
and 3. Incidence of hyperglycemia was also reported in patients treated in the Phase 1 trials of 
dual PI3K/mTOR inhibitors such as PF-04691502 and GSK2126458, and also in pan class I 
PI3K inhibitors such as BKM120 (Wen, Lee, Reardon, Ligon, & Alfred Yung, 2012). Crosstalk 
between PI3K pathway and glucose/insulin regulation has been reported in preclinical studies, 
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where PI3K inhibition has resulted in hyperinsulinemia and hyperglycemia (Hong et al., 2012; 
Ihle et al., 2009). Overall, the adverse events mirrored the overlapping toxicity profile of PI3K 
and mTOR inhibitors.  
We performed a pharmacodynamic analysis using patient-derived mononuclear cells 
from day 1 (pre-treatment) and 28 (post-treatment) for quantification of downstream substrate of 
mTOR, phosphorylated p70S6K (Thr389) and total p70S6K, phosphorylated Akt (Ser473) and 
total Akt, phosphorylated S6K and S6K, phosphorylated 4E-BP1 (TS65).  Though there was a 
trend towards decreased phosphorylation of 4E-BP1 in some patients the inter-patient variability 
in addition to the low number of patients per treatment cycle preclude any conclusive statement 
regarding the efficacy. Expression and quantitative analysis of these biomarkers from blood 
mononuclear cells has been reported to challenging (Shapiro et al., 2014) and more invasive skin 
or hair biopsies are regularly utilized to overcome this limitation (Rodon et al., 2013).  
Clinical pharmacokinetics of BEZ235 was not described at the time of this study.  We 
delineated the pharmacokinetics of BEZ235 at 200, 400 and 800 mg after single oral dose (day 
1) and at steady state (day 28). Plasma Cmax was 45.2 ±11.4, 101.8 ±22.4 and 243.0 ±52.7 ng/mL 
and corresponding BEZ235 exposure, AUC0-24, was 433.4 ± 96, 741.3 ± 171.2 and 2081.5 ± 
666.2 hr*ng/mL for 200, 400 and 800 mg BEZ235 doses, respectively . The terminal half-life of 
BEZ235 after single dose showed higher inter-individual variability and ranged between 3.2 - 8.6 
hours. Earlier this year, Bendell et.al, reported the findings from a Phase I study evaluating 
BEZ235 at twice daily (BID) dosing in patients with advanced solid tumors (J. C. Bendell et al., 
2015). The exposure of once daily dose of BEZ235 from our study was comparable to BID 
dosing reported by Bendell et.al, AUC0-24 at 400 mg once daily (741.3 ng*hr/mL) was close to 
200 mg twice daily (752.9 ng*hr/mL) (J. C. Bendell et al., 2015). Steady state levels of BEZ235 
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showed significant accumulation and ranged from 2.4 – 8.1 folds. BEZ235 plasma Cmax 
increased from 0.3 μM (range: 0.04 - 0.9 μM) on day 1 to 0.9 μM (range: 0.06 – 4.2 μM). Steady 
state average concentration of BEZ235 estimated from clearance ranged between 0.1 – 16.7 µM. 
This concentration is multifold higher than the IC50 of BEZ235 inhibition of PI3K and mTOR, 
however, there is no evidence if this plasma concentration correlates with sustained PI3K/mTOR 
inhibition in humans.  The terminal half-life at steady state based on BEZ235 sampling up to 72 
hours post dose ranged between 15 – 43 hours, indicating a slower terminal elimination phase. 
Despite the inter-subject variability, BEZ235 Cmax and AUC0-24 increased in a linear dose-
proportional manner as apparent from the linear regression and power model. It is not possible to 
determine absolute oral bioavailability, however the oral clearance (CL/F; total systemic 
clearance normalized to the bioavailable fraction, F) ranged from approximately 630 L/hr to 780 
L/hr, which is markedly higher than the total hepatic blood flow of 90 L/hr and effective renal 
plasma flow of approximately 40 L/hr, indicating that the bioavailable fraction, F, is an 
extremely small numerical value. Pre-clinical studies in rat and dog show that BEZ235 has a low 
oral bioavailability around 20 - 34%.  However, in humans it appears to be much lower than that. 
The overall pharmacokinetics was associated with marked inter-subject variability, which is 
often observed with compounds with low oral bioavailability.  Additionally, the rate of 
absorption also varied with the Tmax ranging from 2 – 8 hrs. One primary reason for low oral 
bioavailability and highly variable pharmacokinetics of BEZ235 can be attributed to its low 
aqueous solubility (0.01 mg/mL).  Thus, for this early phase clinical pharmacology study 
BEZ235 was formulated as a SDS special delivery system (SDS) formulation, in an attempt to 
overcome poor solubility and to reduce the inter-individual variability in pharmacokinetics. This 
formulation in the form of a sachet was taken with a light meal or yogurt. Despite these efforts, 
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inter-individual variability in BEZ235 pharmacokinetics was very high and the oral availability 
was low. Similarly, Bendell et al, reported a highly variable pharmacokinetics of BEZ235 in a 
Phase I study at doses 300 – 600 mg given twice daily using a similar SDS sachet formulation (J. 
C. Bendell et al., 2015).  
BEZ235 pharmacokinetics indicates plasma concentrations well above the inhibitory 
potential for all the isoforms of PI3K and mTOR. However, we did not see any efficacy in the 
clinical trial. In most cases there was no improvement in progression free survival or objective 
response rate based on tumor measurements. Novartis decided to terminate the trial and stop 
further development of the compound. The observed toxicities of BEZ235 might be due to its 
broad-spectrum off-target effects, as well as adverse events due to the inhibition all class I PI3K 
isoforms regardless of their contribution to tumorigenesis. Our studies underscore the 
significance of PI3K isoform selective inhibitors that might have a better safety to efficacy 
profile. 
Everolimus pharmacokinetics was evaluated on day 1 and day 28. Though we did not 
have a separate cohort where everolimus was dosed alone, intensive pharmacokinetic sampling 
on day 1 and day 28 enabled for a systematic analysis of drug interaction. On day 1, everolimus 
blood Cmax was 14.08 ±1.5 ng/mL and AUC0-24 was 124.32 ± 12.7 ng*hr/mL. On day 28, there 
was significant increase in both Cmax and AUC0-24, Cmax was 31.68 ± 7.4  ng/mL on day 28 and 
AUC0-24 was 218.8 ± 33.26 ng*hr/mL. Similarly, clearance of everolimus (CL/F) decreased from 
24.76 ±2.91 L/h on day 1 to 13.41 ±2.31 L/hr on day 28.  A dose-normalized comparison of 
everolimus exposure in the combination of everolimus and BEZ235 when compared to 
everolimus alone showed that there was a 1.7 fold increase.  Extensive clinical and preclinical 
studies indicate that everolimus undergoes extensive intestinal and first pass hepatic clearance 
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mediated primarily by CYP3A4 metabolism and efflux by P-gp. Several previous publications 
suggest that everolimus is highly susceptible to modulation of CYP3A4 activity and co-
administration with a strong inhibitor such as ketoconazole caused as 4-fold increase in the Cmax 
and 15-fold increase in the AUC0-24. Oral bioavailability (F) can be expressed as a product of 
fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic 
elimination (Fh) (Pang, 2003). Everolimus has a good permeability and solubility and Fa is close 
to 1. On this basis, everolimus can be categorized as a BDDCS class I drug (C. Y. Wu & Benet, 
2005) exhibiting high permeability, and high solubility and extensive metabolism. Yokomasu 
et.al, observed that Fg of everolimus after intra-intestinal administration in rats was 0.21 and Fh 
was 0.87, indicating that almost 80% of everolimus is eliminated in the intestine (Yokomasu et 
al., 2009). Clinically this was proved by observing that the impact of everolimus interaction with 
fluconazole, a CYP3A4 inhibitor, was very strong when given orally compared to when 
fluconazole was given intravenously (Mihara et al., 2008; Pea et al., 2008). Everolimus has a 
narrow therapeutic index and FDA label recommends drug monitoring for everolimus when co-
administered with CYP3A4 and/or P-gp inducers or inhibitors (US-FDA - clinical pharmacology 
and biopharmaceutics review) (Kirchner, Meier-Wiedenbach, & Manns, 2004).   
Correlative studies were performed to investigate the mechanism of this interaction. 
The potential of BEZ235 to modulate CYP3A4 was evaluated in human liver microsomes and 
primary human hepatocytes. It was observed that BEZ235 was not a competitive inhibitor up to 
25 µM concentration. However, it showed a significant inhibition potential in time-dependent 
inhibition studies. Two-step dilution method was used for time dependent inhibition studies, pre 
incubation times up to 60 min. The inactivation efficiency calculated as kinact /KI was 0.00336 
min-1 μM which indicated that BEZ235 is not a potent inhibitor when compared to the 
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inactivation efficiency of fluoxetine which is 0.005 min-1 μM (Ki and kinact of 3 µM and 0.015 
min-1, respectively) (Fahmi et al., 2009). Fluoxetine though a mild time dependent inhibitor of 
CYP3A4, leads to a significant increase in steady state alprazolam levels on multiple dosing 
(Lasher, Fleishaker, Steenwyk, & Antal, 1991).  In studies using primary human hepatocytes, 
BEZ235 was observed to have a potential to induce CYP3A4 mRNA levels; however, there was 
no corresponding increase in CYP3A4 activity. 
A mechanistic static model using “net effect mode” was developed to study the 
complex interaction by multiple mechanisms such as time-dependent inhibition and induction of 
BEZ235. Various surrogates for BEZ235 concentration were used in mathematical model to 
study the mechanism and impact of drug interaction. As previously reported for time dependent 
inhibition and induction, the use of physiologically relevant unbound Cmax for hepatic 
concentrations ([I]H) and gut enterocyte concentrations ([I]g) for BEZ235 was close to the 
observed interaction(Vieira et al., 2014; Vieira et al., 2012). 
Mechanistic PBPK model for BEZ235 was a first order absorption with minimal 
PBPK, which adequately described plasma concentration profile after 200, 400 or 800 mg dose 
of BEZ235. Everolimus PBPK model was an advanced, disposition and metabolism (ADAM) 
model used with a minimum PBPK model. Everolimus PBPK model adequately predicted the 
concentration time profile in cancer patients at 5 mg and 10 mg once daily when given alone. 
Further, everolimus interaction with other CYP3A4 inhibitors such as ketoconazole, 
erythromycin, verapamil, and rifampin were performed to qualify the PBPK model. These 
inhibitors captured both competitive and time dependent inhibition of CYP3A4, as well as 
induction of CYP3A4. Model prediction was within 30-40% prediction error in all the cases 
elucidating the suitability of PBPK model. BEZ235 interaction with everolimus was performed 
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using healthy volunteer population in Simcyp. Everolimus Cmax and AUC0-24 on day1 and day 28 
were in good agreement with the observed from the clinical trial. Further, effect of BEZ235 on 
the differential expression of CYP3A4 along the small intestine, and the consequence to the 
fraction of everolimus escaping metabolism was simulated using ADAM model in Simcyp 
(Jamei et al., 2009; Rowland et al., 2011; Rowland Yeo, Jamei, Yang, Tucker, & Rostami-
Hodjegan, 2010). There was a significant decrease in gut CYP3A4 activity leading to an increase 
in everolimus Fg and there was a minimal reduction in hepatic CYP3A4 activity. The PBPK 
model simulation using time dependent and induction potential of BEZ235 is consistent with the 
observed everolimus interaction, further suggesting that the mechanism of the interaction. 
BEZ235 was not observed to inhibit P-gp in Caco-2 uptake studies, indicating P-gp might not 
play a role in this interaction. From simulations, it is evident that CYP3A4 activity starts to 
decline after 3 h of BEZ235 dosing. Since everolimus and BEZ235 are dosed simultaneously, 
there is minimal to no interaction observed on day 1. However, there is a significant interaction 
observed on day 28. 
Correlative studies and mechanistic modeling was performed in an attempt to better 
understand the toxicity and lack of efficacy in the combination therapy. There are number of 
combinations of MTAs showing significant synergism in pre-clinical models, however only a 
few have shown therapeutic benefit at the clinic. Pharmacokinetics interaction of the 
combination drug and also the lack of it could be a reason of increased toxicity and decreased 
efficacy when translating the pre-clinical success. Here we showed that with the proper 
understanding of pharmacokinetic disposition pathways and investigations of mechanisms of 
interaction can facilitate better understanding of the exposure relation to efficacy and toxicity. 
141 
 
These results illustrate the importance of evaluating mechanistic pharmacokinetic interaction 
studies to understand the complex interaction of MTA’s. 
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7 Conclusion 
Our studies provide the first detailed report on the pharmacokinetics of dual 
PI3K/mTOR inhibitor, BEZ235, in combination with mTOR inhibitor, everolimus, in patients 
with advanced solid malignancies. BEZ235 exhibited a dose proportional pharmacokinetics in 
the dose range 200 – 800 mg. However, it was marked with high inter-individual variability and 
low oral bioavailability. The terminal half-life of BEZ235 after single dose was short ranging 
between 3.2 - 8.6 hours. At steady state, BEZ235 levels were approximately 3-fold higher than 
that following single dose administration. Everolimus pharmacokinetics at 2.5 mg/day was 
characterized after a single dose and on steady state. We observed a significant pharmacokinetic 
interaction in the combination marked by significant increase in everolimus levels on day 28. 
The drug interaction in the combination was delineated by both a non-compartmental analysis 
and a population based pharmacokinetic modeling. Correlative in vitro studies using human 
microsomes and hepatocytes were preformed to investigate the mechanism of this interaction. 
BEZ235 was identified to be a time-dependent inhibitor of CYP3A4 with kinact of 0.0175 min-1 
and KI of 5.213 μM. A mechanistic PBPK model was developed based on the in vitro findings, 
which provided further insights into the mechanism of this interaction. PBPK model simulations 
indicated that BEZ235 resulted in a 5 fold reduction of gut CYP3A4 activity, leading to a 
significant decrease in everolimus clearance, which is predominantly metabolized in gut.  These 
findings highlight that BEZ235 may also impact pharmacokinetics of other CYP3A4 substrates, 
especially the ones with significant gut metabolism.  Overall, the clinical outcome in the 
combination of BEZ235 and everolimus was disappointing with overlapping toxicities leading to 
early termination of the trial. The reasons for this lack of response are not clear but the PK data 
suggest that the systemic exposure to BEZ235 and/or everolimus exceed the levels where 
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significant target inhibition was noted in vitro.   However, a correlation between PK parameter 
and PD response or dose-response relationship in the clinical setting is urgently needed to 
underscore the strategic significance to continue clinical research on such compounds.  We 
believe our results have contributed to this effort and ultimately facilitate the development of 
novel anti-cancer therapies including PI3K/mTOR inhibitors.   
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